Cumulative Subject Index for Volumes 76–79

Gynecologic Oncology 79, 533–551 (2000) doi:10.1006/gyno.2000.6063, available online at http://www.idealibrary.com on

Cumulative Subject Index for Volumes 76 –79 1,2 A Abdominal sacral colpopexy in gynecologic cancer patients, long-term follow-up, case report and literature review, 75, 504; letter to editor, 77, 483; reply, 484 Abstracts Society of Gynecologic Oncologists, Thirty-first Annual Meeting, February 2000, 76, 230; erratum, 77, 222 Western Association of Gynecologic Oncologists, Twenty-ninth Annual Meeting, May 2000, 79, 133 Acknowledgment 2000 manuscript reviewers, 79, 526 Actinomycin D, see Dactinomycin Actinomycosis pelvic, CT-guided core needle biopsy diagnosing, case report, 79, 318 Adeno-associated virus 2 infection in HPV-associated premalignant disease of cervix, possible protective role, 78, 342 Adenocarcinoma of GI epithelial origin, arising from benign cystic teratoma of the ovary, case report, 70, 418; letter to editor, 77, 478 Adnexal masses asymptomatic, classification by ultrasound, MRI, and PET, 77, 454 ovarian capillary hemangioma presenting as, with elevated CA 125, case report, 76, 130 Age impact on outcome in invasive cervical carcinoma, 79, 107 and ovarian volume, relationship, 77, 410 as prognostic factor for recurrence of endometrial carcinoma, 79, 79 specific survival, in endometrioid adenocarcinoma of uterus, 79, 86 Alkaline phosphatase human secreted, as surrogate marker for ovarian carcinoma xenograft growth and anticancer drug efficacy in vivo, 78, 373 Allelic imbalance in lichen sclerosus, hyperplasia, and intraepithelial neoplasia of vulva, 77, 171 Alternative therapies frequency of use in gynecological cancers, letter to editor, 79, 336; reply, 336 herbal, use by patient with squamous cell cervical carcinoma, case report, 77, 190 Anastomosis low-rectal, and continent urinary diversion, in patients undergoing exenterative procedures for recurrent gynecological cancers, incidence of complications, 78, 208 Anastrozole in advanced recurrent or persistent endometrial carcinoma, phase II Gynecologic Oncology Group study, 78, 212 Angiogenesis in epithelial ovarian cancer, correlation with thymidine phosphorylase expression, 77, 26 1 2

Angiography power Doppler, and blood flow velocity waveforms, in prediction of cervical malignancy, 79, 181 Animal models SCID murine– human xenograft, in development and assessment of general theory of cervical carcinogenesis, 77, 137 Antisense RNA 2-5A telomerase-directed, induction of apoptosis in ovarian carcinoma cell lines, 76, 183 Anxiety in epithelial ovarian cancer patients, relationship with health and demographic variables, 78, 302 Apolipoprotein D in epithelial ovarian carcinoma, expression and clinical significance, 76, 340 Apoptosis cervical carcinoma cells, dexamethasone treated, RU486-induced increase through HPV E6/E7 modulation, 77, 177 as early event in progestin therapy for endometrial hyperplasia, 79, 169 endometrial adenocarcinoma cells, induction by antitumor lipoprotein fraction of rice bran, 76, 170 endometrial carcinoma cells multiparameter flow cytometric study, 77, 11 role of bcl-2 and bcl-XL expression, 77, 419 epithelial ovarian cancer, correlation with thymidine phosphorylase expression, 77, 26 ovarian carcinoma cell lines, induction by 2-5A antisense directed against telomerase RNA, 76, 183 Appendiceal malignancies mimicking advanced-stage ovarian carcinoma, case report, 78, 388 Ascites elevated serum CA 125 levels in hemodialysis patients with, 77, 254 and hepatitis C, extreme elevation of CA 125 associated with, letter to editor, 70, 441; letter to editor; 76, 141; reply, 76, 141 Ashkenazi Jews ovarian cancer patients, founder BRCA1/2 mutations among, 78, 148 ATP cell viability assay in prediction of chemoresponse in Pt-resistant epithelial ovarian carcinoma, 76, 405 ATP tumorchemosensitivity assay in stage III ovarian carcinoma, correlation with drug response, 77, 258 Atypical glandular cells of undetermined significance on ThinPrep Papanicolaou smears, significance, 78, 245 Atypical squamous cells of undetermined significance on ThinPrep Papanicolaou smears, significance, 79, 44 B Bartholin’s gland carcinoma high-dose-rate interstitial brachytherapy in, case report, 77, 193 bcl-2 expression in cervical carcinomas and premalignant lesions, clinical significance, 77, 129

Boldface numbers indicate volume; lightface numbers indicate pagination. Page numbers preceded by an “S” are for the supplement issue Vol. 78, No. 3, Part 2 of 2 parts. 533

0090-8258/00 $35.00 Copyright © 2000 by Academic Press All rights of reproduction in any form reserved.

534

CUMULATIVE SUBJECT INDEX

endometrial carcinoma, 77, 419 endometrial epithelium, multiparameter flow cytometric study, 77, 11 epithelial ovarian carcinoma, prognostic value at median follow-up of 60 months, 77, 278 bcl-XL expression in endometrial carcinoma, 77, 419 Bethesda system early cervicocarcinoma precursor in, letter to editor, 76, 144 Bladder motor innervation of, identification and preservation in radical hysterectomy type III, 79, 154 Bleomycin and cisplatin and etoposide, for ovarian endodermal sinus tumor in pregnancy, case report and literature review, 72, 123; letter to editor, 78, 265; reply, 266 Blood flow velocity ultrasound-derived peak systolic, correlation with thymidine phosphorylase expression in epithelial ovarian cancer, 77, 26 waveforms, and power Doppler angiographic appearance, in prediction of cervical malignancy, 79, 181 Bowel obstruction in advanced ovarian carcinoma, management options and patient desires, editorial, 75, 311; letter to editor, 78, 394; reply, 395 Brachytherapy high-dose intracavitary, and high external parametrial radiation, in cervical carcinoma, relationship with radiation proctitis, 79, 406 high-dose-rate interstitial, in Bartholin’s gland carcinoma, case report, 77, 193 low-dose-rate intracavitary, in cervical carcinoma, acute problems associated with, 76, 67 one versus two intracavitary applications, in early-stage cervical cancer patients undergoing definitive radiation therapy, 78, 32 vaginal vault, postoperative, in high-risk node-negative stage I endometrial carcinoma, local recurrence following, 79, 490 BRCA1 breast cell line with 185delAG mutation, establishment and characterization, 77, 121 expression in sporadic ovarian cancer, 76, 294 founder mutations among Ashkenazi ovarian cancer patients, 78, 148 gene therapy in ovarian cancer, new generation retroviral vector for, preclinical studies, 79, 471 germline mutation linkage with primary cancer of the Fallopian tube, molecular evidence, 76, 45; letter to editor, 78, 263; response, 264 Xp22.2-3 LOH associated with, 76, 418 mutation carriers, histology of prophylactically removed ovaries from, comparison with noncarriers in hereditary breast cancer syndrome kindreds, 78, 278 mutation status in patients with double primary tumors of breast and ovary, 79, 74 what do we know? what do we think we know? what do we really need to know?, editorial, 76, 291 BRCA2 founder mutations among Ashkenazi ovarian cancer patients, 78, 148 germline mutation in fallopian tube carcinoma, case report, 77, 319 in ovarian carcinosarcoma patient, evidence for monoclonal origin, case report, 76, 226 mutation carriers, histology of prophylactically removed ovaries from, comparison with noncarriers in hereditary breast cancer syndrome kindreds, 78, 278 mutation status in patients with double primary tumors of breast and ovary, 79, 74

Breast cancer, see also Hereditary breast– ovarian cancer syndrome cell line MCF-7, EGF-induced c-fos expression, inhibition by LHRH analogs, 78, 194 cell line with BRCA1 185delAG mutation, establishment and characterization, 77, 121 heterologous metaplastic, simulating primary uterine malignancy, uterine metastasis from, case report, 77, 216 low-grade endometrial stromal sarcoma of ectocervix following, case report, 79, 120 preinvasive, tenascin as marker for malignant potential, 79, 372 in premenopausal women, failure of goserelin ovarian ablation in, case reports, 76, 126 primary, ovarian cancer patients with previous history of, clinical characteristics and BRCA1–2 mutation status, 79, 74 tamoxifen-treated patients endometrial histopathology in, review of 700 cases, 78, 181 postmenopausal, long-term transvaginal ultrasonographic endometrial follow-up, 74, 222; letter to editor, 76, 423; reply, 423 Brenner tumor ovarian signet ring stromal tumor occurring with, case report, 77, 323

C E-Cadherin complex proteins, expression in advanced-stage ovarian carcinoma, correlation with survival, 79, 362 expression in cervical intraepithelial neoplasia in HIV positive and negative women, correlation with HPV status, 76, 56 Cancer antigens, see also Squamous cell carcinoma antigen CA 19-9, as marker of recurrence in borderline ovarian tumors, 78, 16 CA 125 decline in levels in ovarian cancer patient with progression of measurable disease, case report, 77, 321 elevated in hemodialysis patients with peritoneal, pleural, or pericardial fluids, 77, 254 in ovarian capillary hemangioma presenting as adnexal mass, case report, 76, 130 in patient presenting with fever and pelvic mass diagnosed as tuberculosis peritonitis, case report, 77, 471 extreme elevation from hepatitis C and ascites, letter to editor, 70, 441; letter to editor; 76, 141; reply, 76, 141 as marker of recurrence in borderline ovarian tumors, 78, 16 measurement in trophoblastic disease, 78, 39 in preoperative prediction of optimal resectability in advanced ovarian cancer, 77, 227 editorial, 77, 225 pretherapeutic serum levels, as prognostic factors in recurrent ovarian carcinoma, 79, 416 serum levels in advanced epithelial ovarian carcinoma, effects of topotecan, 77, 383 after three chemotherapy courses in ovarian cancer patients, prognostic significance, 79, 444 in ovarian cancer patients, effects of paclitaxel, 76, 326 Carbohydrate antigens expression in advanced-stage ovarian carcinoma, correlation with metastasis, 77, 35 Carboplatin based chemotherapy, antiemetic efficacy of oral ondansetron plus iv dexamethasone in patients with gynecologic malignancies, 78, 43 and cyclophosphamide, etoposide, and paclitaxel with G-CSF as first-line therapy in advanced-stage ovarian carcinoma, phase II trial, 77, 271 intraperitoneal administration in ovarian carcinoma, complications, 79, 420

CUMULATIVE SUBJECT INDEX and paclitaxel versus ifosfamide/platinum, in malignant mixed Mu¨llerian tumor of ovary, 79, 196 rapidly growing squamous cell ovarian carcinoma successfully controlled by weekly administration, case report, 79, 515 weekly administration as strategy for severe treatment-related emesis, letter to editor, 78, 265 Carcinoembryonic antigen as marker of recurrence in borderline ovarian tumors, 78, 16 as prognostic indicator in low-risk stage IB-IIA squamous cell carcinoma of cervix, 76, 103 Carcinogenesis cervical general theory of, development and assessment with SCID murine– human xenograft model, 77, 137 microsatellite instability as late event in, 79, 201 ␤-Catenin expression in advanced-stage ovarian carcinoma, correlation with survival, 79, 362 – T-cell factor pathway, activation in ovarian cancer, 77, 97 Catheters intraperitoneal, erosion resulting in enterovaginal fistula, case report, 77, 327 Cavitational ultrasonic surgical aspiration in treatment of vaginal intraepithelial neoplasia, 78, 235 CD31 expression in primary and metastatic epithelial ovarian cancer, 78, 130 CD35 expression in benign and malignant endometrial tissue, 76, 176 CD44 expression in cervical squamous neoplasia, as predictor of microinvasion, 76, 73 Mu¨llerian serous carcinomas, 79, 430 expression in cervical intraepithelial neoplasia in HIV positive and negative women, correlation with HPV status, 76, 56 isoforms, expression in clear cell ovarian carcinoma in, 79, 187 CD46 expression in benign and malignant endometrial tissue, 76, 176 CD55 expression in benign and malignant endometrial tissue, 76, 176 CD59 expression in benign and malignant endometrial tissue, 76, 176 Cdk4 and p16, inverse expression in epithelial ovarian tumors, 79, 230 CEA, see Carcinoembryonic antigen c-erbB-2 expression in advanced-stage ovarian carcinoma, correlation with survival, 79, 362 c-erbB-3/4 expression in gestational trophoblastic disease, relationship with postmolar tumor development, 77, 389 Cervical adenocarcinoma clear cell behavior and relationship to intrauterine DES exposure, Distinguished Professor Series, 76, 147 stage IB–IIB, surgically treated, in women not exposed to DES in utero, pathology and prognosis, 76, 331 early stage, with negative lymph nodes, laparoscopic port-site metastasis in, case report, 75, 155; letter to editor, 77, 339; reply, 339 and hormone replacement therapy, relationship, 77, 149 in situ conservative management of, 79, 6 experience with 100 cases, 79, 207

535

margins must be clear, editorial, 79, 4 recurrent invasive adenocarcinoma after hysterectomy for, case report, 77, 334 ligand and receptor expression, relationship to p27 Kip1 expression, 78, 106 rising incidence relative to squamous cell cervical carcinoma, 24-year population based study, 78, 97 squamous, unusual recurrence after conservative surgery, case report, 76, 409 stage IA, bilateral pelvic lymph node metastases in, case report, 77, 467 stage IA 1, prospective management by conization alone to preserve fertility, preliminary report, 78, 217 stage IB, prognosis, comparison with squamous cell carcinoma of cervix, 79, 289 villoglandular, well-differentiated HPV-positive, case report and literature review, 77, 473 Cervical carcinoma advanced, radiotherapy in patient’s perspective on physical symptoms after, 76, 14 psychological and social effects of, 76, 5 with aggressive tumor growth, possible autocrine stimulation by G-CSF and IL-6, case report, 78, 380 barrel-shaped endophytic, radiation dose and residual tumor, prognostic significance, 76, 373 carcinogenesis, microsatellite instability as late event in, 79, 201 cell lines CaSki, tumorigenicity, effects of HPV16 E7 antisense RNA after retrovirus-mediated delivery, 78, 293 hepatocyte growth factor promotion of scattering and morphogenesis in vitro, 78, 158 chemoradiation in better treatments that cost more, editorial, 78, 1 concurrent cisplatin-based, cost effectiveness, 78, 3 elevated topoisomerase I activity as target for, 79, 272 dexamethasone treated cells, RU486-induced increase in radiosensitivity and apoptosis through HPV E6/E7 modulation, 77, 177 early-stage combined laparoscopic and vaginal radical surgery in, 79, 59 laparoscopic assessment of sentinel lymph node, 79, 411 one versus two intracavitary brachytherapy applications in patients undergoing definitive radiation therapy, 78, 32 guidelines for referral to gynecologic oncologist, rational and benefits, 78, S9 hematogenous skin metastasis at primary presentation, 76, 416 high-risk, chemotherapy, radiotherapy, or observation after radical hysterectomy, randomized prospective trial, 73, 196; letter to editor, 77, 340; reply, 341 HPV-16, E6 sequence variations in, differential distribution, 79, 11 incidence rates, effects of hysterectomy prevalence, letter to editor, 79, 337 intraoperative lymphatic mapping in patients undergoing radical hysterectomy for, 79, 238 invasive age, race, and comorbid illness in, impacts on outcome, 79, 107 histologic variants, chromosome 4 deletions in, 79, 90 and HIV infection, in South Africa, 77, 460 power Doppler angiographic appearance and blood flow velocity waveforms, 79, 181 therapeutic decisions, effects of MRI, 79, 485 left extraperitoneal laparoscopic para-aortic lymphadenectomy in, technical development and results, 77, 87 locally advanced cisplatin and 5-FU in preoperative chemoradiation, phase I–II trial, 78, 324 significance of thrombocytosis in, Gynecologic Oncology Group Study, 78, 137

536

CUMULATIVE SUBJECT INDEX

low-dose-rate intracavitary brachytherapy in, acute problems associated with, 76, 67 metastatic bulky/clinically evident, assessment of disease extent, pretreatment studies, 76, 383 to para-aortic lymph nodes, survival after extended field irradiation, 79, 399 neoadjuvant chemotherapy in, NK cell activity in presence of IL-12 as prognostic assay, 78, 318 neoplastic progression, role of low-grade squamous intraepithelial lesion, letter to editor, 76, 144 post-therapy surveillance of patients, outcomes analysis, 78, 187 and premalignant lesions, bcl-2 and p53 expression, clinical significance, 77, 129 progression from CIN, associated disappearance of connective tissue-activating peptide III expression, 79, 23 PTEN/MMAC1 tumor suppressor gene in, mutational analysis, 76, 193 radiation proctitis in, relationship with high external parametrial radiation and high-dose intracavitary brachytherapy, 79, 406 recurrent preirradiated, efficacy of gemcitabine in, letter to editor, 78, 76 in search of clinical pathways: illumination or illusion, commentary, 79, 143 squamous cell advanced, persistent, or recurrent, cisplatin and gemcitibine phase II study, 76, 63 advanced or recurrent, cisplatin and pentoxifylline, phase II trial, 79, 64 CD44 expression as predictor of microinvasion, 76, 73 gemcitibine therapy in, phase II study, 76, 204 and hormone replacement therapy, relationship, 77, 149 incidence and survival relative to cervical adenocarcinoma, 24-year population based study, 78, 97 patient use of alternative herbal therapies in, case report, 77, 190 preservation of fertility after complete response to primary systemic chemotherapy, case report, 77, 213 previously-treated, topotecan therapy in, phase II study, 77, 446 prognosis, comparison with stage IB cervical adenocarcinoma, 79, 289 radiation therapy in elderly patient, efficacy and toleration, 77, 116 serum Cyfra 21-1, SCC-Ag, and TPA levels, as predictors of lymph node metastasis or prognosis, 77, 164 stage IB MIB-1 labeling index as prognostic factor, 76, 97 with negative lymph nodes, laparoscopic port-site recurrence after surgery, case report, 79, 324 stage IB–IIA, CEA, TPA, and SCC-Ag as prognostic factors, 76, 103 squamous cell carcinoma antigen and leupin/SCCA-2 immunoreactivity, implications for tumor marker detection, 78, 62 stage IA, MRI findings, correlation with invasive cervical biopsy, 79, 451 stage IB abandoned radical hysterectomy in, frequency and patient outcomes, Gynecologic Oncology Group Study, 79, 350 with lymph node metastasis or parametrial invasion, cyclooxygenase-2 expression, 76, 320 stage IB, IIA, and IIB, node-positive, risk factors after radical hysterectomy and postoperative pelvic irradiation, 77, 305 stage IB2–IIIB, neoadjuvant intraarterial infusion chemotherapy in, 77, 264 stage IIA, with cardiac metastasis, immunohistochemistry, flow cytometry, and virology findings, case report, 76, 133 stage II and III, radiotherapy in, clinical outcomes in black versus white women, 79, 357 stage IIIB, radiotherapy for, proliferation assessment with MIB-1 labeling index as prognostic factor, 79, 300 staging, utility of cytoscopy in, 76, 200 value of woman’s perceived quality of life after, editorial, 76, 3

Cervical intraepithelial neoplasia atypical nuclei in, identification by fractal analysis, 75, 78; letter to editor, 78, 78; reply, 79 bcl-2 and p53 expression, clinical significance, 77, 129 E-cadherin expression in HIV positive and negative women, correlation with HPV status, 76, 56 high-grade, and cervical atrophy, differentiation, role of proliferative activity measurement in, 79, 225 indole-3-carbinol in treatment of, placebo-controlled trial, 78, 123 lesions, lymphocyte infiltrates in HIV positive patients, 76, 315 low-grade squamous lesions, role in cervical neoplastic progression, letter to editor, 76, 144 persistent/recurrent lesions, predictive factors after conization, 76, 311 progression to cervical cancer, associated disappearance of connective tissue-activating peptide III expression, 79, 23 recurrent abnormal cytology and residual disease, effects of combined colposcopy, loop conization, and laser vaporization in, 78, 47 type III persistence of HPV infection after therapeutic conization for, as indicator of recurrence risk, 79, 294 radical hysterectomy after conization for, predictive factors for residual disease, 79, 284 Cervix bulky barrel-shaped lesion of, primary surgery and postoperative chemotherapy, 78, 313 general theory of carcinogenesis, development and assessment with SCID murine– human xenograft model, 77, 137 glycodelin-A expression, 79, 216 HPV-associated premalignant disease of, possible protective role of adenoassociated virus 2 infection, 78, 342 Wilms’ tumor of, case report and literature review, 76, 107 Cetrorelix effects on EGF-induced c-fos expression in gynecological cancers, 78, 194 Chemoradiation in cervical cancer, elevated topoisomerase I activity as target for, 79, 272 preoperative, cisplatin and 5-FU in locally advanced cervical carcinoma, phase I–II trial, 78, 324 Chemoresistance epithelial ovarian cancer to primary cisplatin and paclitaxel, correlation with EDR assay, 70, 392; letter to editor, 76, 143 Chemosensitivity Pt-resistant epithelial ovarian carcinoma, ATP cell viability assay in prediction of, 76, 405 Chemotherapy actinomycin D, etoposide, and methotrexate, in high-risk gestational trophoblastic disease, 78, 28 anastrozole, in advanced recurrent or persistent endometrial carcinoma, phase II Gynecologic Oncology Group study, 78, 212 bleomycin, cisplatin, and etoposide, for ovarian endodermal sinus tumor in pregnancy, case report and literature review, 72, 123; letter to editor, 78, 265; reply, 266 carboplatin antiemetic efficacy of oral ondansetron plus iv dexamethasone in patients with gynecologic malignancies, 78, 43 and cyclophosphamide, etoposide, and paclitaxel with G-CSF as first-line therapy in advanced-stage ovarian carcinoma, phase II trial, 77, 271 and paclitaxel versus ifosfamide/platinum, in malignant mixed Mu¨llerian tumor of ovary, 79, 196 rapidly growing squamous cell ovarian carcinoma successfully controlled by weekly administration, case report, 79, 515 weekly administration as strategy for severe treatment-related emesis, letter to editor, 78, 265

CUMULATIVE SUBJECT INDEX carboplatin/cisplatin intraperitoneal administration for ovarian carcinoma, complications, 79, 420 CI-958, in treatment of Pt-refractory ovarian carcinoma, Gynecologic Oncology Group phase II trial, 79, 463 cisplatin concurrent with radiation, in cervical cancer, cost effectiveness, 78, 3 and 5-fluorouracil intraperitoneal therapy in previously treated ovarian carcinoma , phase II study, 77, 433 in preoperative chemoradiation for locally advanced cervical carcinoma, phase I–II trial, 78, 324 and gemcitibine, in advanced, persistent, or recurrent squamous cell carcinoma of cervix, phase II study, 76, 63 with ifosfamide, in treatment of uterine carcinosarcoma, phase III trial, 79, 147 intraperitoneal, and iv paclitaxel, in treatment of epithelial ovarian carcinoma with positive second look, 79, 28 and paclitaxel in advanced or recurrent endometrial carcinoma, long-term results of phase II multicenter study, 78, 52 in advanced-stage borderline ovarian tumors, surgical response, letter to editor, 77, 343 in epithelial ovarian carcinoma in HIV-infected patient, case report, 76, 118 primary, response in epithelial ovarian cancer, correlation with EDR assay, 70, 392; letter to editor, 76, 143 and pentoxifylline, in advanced/recurrent squamous cell carcinoma of the cervix, phase II trial, 79, 64 cyclophosphamide, with secondary hemorrhagic pyelitis, ureteritis, and cystitis, case report and literature review, 76, 223 docetaxel associated extravasation causing significant delayed tissue injury, case report, 78, 259 in chemoresistant gestational choriocarcinoma, letter to editor, 79, 524 doxorubicin, liposomal in advanced ovarian carcinoma, phase II study, 78, 143 in Pt/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of peritoneum, phase II trial, 78, 369 etoposide, cyclophosphamide, dactinomycin, methotrexate, and vincristine, in recurrent placental site trophoblastic tumor affecting prolonged remission, case report, 76, 115 gemcitibine, in squamous cell cervical carcinoma, phase II study, 76, 204 in gestational trophoblastic disease, influence of mode of evacuation, 78, 309 in high-risk cervical carcinoma, versus radiotherapy or observation after radical hysterectomy, randomized prospective trial, 73, 196; letter to editor, 77, 340; reply, 341 ifosfamide, single-agent, in treatment of uterine sarcoma, safety and efficacy, 78, 221 intraperitoneal, in ovarian carcinoma, real-time ultrasonographically guided transvaginal instillation, case report, 79, 332 neoadjuvant in cervical carcinoma, NK cell activity in presence of IL-12 as prognostic assay, 78, 318 intraarterial infusion, in stage IB2–IIIB cervical carcinoma, 77, 264 paclitaxel, single-agent, in treatment of relapsed ovarian carcinoma after paclitaxel and platinum as initial therapy, 79, 211 platinum-based, high- versus standard-dose, in advanced ovarian carcinoma, randomized trial, 78, 361 postoperative, in bulky barrel-shaped lesion of cervix, 78, 313 primary systemic, preservation of fertility after complete response of squamous cell cervical carcinoma, case report, 77, 213 prolonged platinum-based, with aggressive surgery, in long-term ovarian cancer survivor, case report, 78, 261

537

salvage, after PBSCT-supported high-dose chemotherapy, efficacy and hematologic toxicity in recurrent ovarian cancer, 77, 48 stage III ovarian carcinoma response to, correlation with ATP tumorchemosensitivity assay, 77, 258 topotecan three-day therapy every 21 days in Pt- and paclitaxel-refractory ovarian carcinoma, phase II evaluation, 79, 116 for recurrent epithelial ovarian carcinoma, phase I trial, 79, 495 24-hour continuous infusion, in recurrent, potentially Pt-sensitive ovarian cancer, phase II Gynecologic Oncology Group study, 77, 112 in recurrent fallopian tube carcinoma affecting complete response, case report, 76, 128 weekly 72-hour infusion in Pt- and paclitaxel-resistant ovarian carcinoma, phase II and pharmacokinetic study, 78, 228 Choriocarcinoma gestational, chemoresistant, docetaxel chemotherapy in, letter to editor, 79, 524 uterine, coexistent with malignant mixed mesodermal tumor, case report, 79, 499 Choroid metastasis to, as initial symptom of recurrence of endometrioid ovarian adenocarcinoma, case report, 77, 219 Chromosome 4 deletions in invasive cervical carcinoma among histologic variants, 79, 90 Chromosome Y pregnancy in woman with, after removal of ovarian dysgerminoma, case report, 79, 519 CI-958 in treatment of Pt-refractory ovarian carcinoma, Gynecologic Oncology Group phase II trial, 79, 463 CIN, see Cervical intraepithelial neoplasia Cisplatin and bleomycin and etoposide, for ovarian endodermal sinus tumor in pregnancy, case report and literature review, 72, 123; letter to editor, 78, 265; reply, 266 concurrent with radiation, in cervical cancer, cost effectiveness, 78, 3 and cyclophosphamide and paclitaxel, with G-CSF, in treatment of primary advanced epithelial ovarian carcinoma, 79, 97 and 5-FU intraperitoneal therapy in previously treated ovarian carcinoma , phase II study, 77, 433 in preoperative chemoradiation for locally advanced cervical carcinoma, phase I–II trial, 78, 324 and gemcitibine, in advanced, persistent, or recurrent squamous cell carcinoma of cervix, phase II study, 76, 63 with ifosfamide, in treatment of uterine carcinosarcoma, phase III trial, 79, 147 intraperitoneal versus iv, with iv cyclophosphamide and epidoxorubicin in advanced epithelial ovarian carcinoma after optimal cytoreduction, randomized trial, 76, 157 and iv paclitaxel, in treatment of epithelial ovarian carcinoma with positive second look, 79, 28 for ovarian carcinoma, complications, 79, 420 ovarian cancer sensitivity, effects of glutathione detoxification system, 76, 362 and paclitaxel in advanced or recurrent endometrial carcinoma, long-term results of phase II multicenter study, 78, 52 in advanced-stage borderline ovarian tumors, surgical response, letter to editor, 77, 343 in epithelial ovarian carcinoma in HIV-infected patient, case report, 76, 118

538

CUMULATIVE SUBJECT INDEX

primary, response in epithelial ovarian cancer, correlation with EDR assay, 70, 392; letter to editor, 76, 143 and pentoxifylline, in advanced/recurrent squamous cell carcinoma of the cervix, phase II trial, 79, 64 Colorectal carcinoma hereditary nonpolyposis endometrial cancer meeting new clinical criteria for, case report, 79, 327 role in susceptibility to gynecologic malignancies, family study with molecular analysis of candidate genes, 77, 18 Colpopexy abdominal sacral, in patients with gynecologic cancers, long-term follow-up, case report and literature review, 75, 504; letter to editor, 77, 483; reply, 484 Colposcopy HPV testing by hybrid capture prior to referral for, in triage of women with abnormal Pap smears, 79, 177 with loop conization and laser vaporization, in cervical dysplasia, 78, 47 Commentaries critique of surgical cytoreduction in advanced ovarian cancer, 78, 269 differentiation between the sick and the dying: an ancient art forgotten in modern medicine, 79, 1 in search of clinical pathways: illumination or illusion–a cervix cancer survey, 79, 143 Comorbid illness impact on outcome in invasive cervical carcinoma, 79, 107 Complement regulatory proteins CD35, CD46, CD55 and CD59, expression in benign and malignant endometrial tissue, 76, 176 Computed tomography preoperative, in prediction of myometrial invasion and extracorporal spread of endometrial cancer, 78, 67 Conization for CIN III, subsequent hysterectomy in, predictive factors for residual disease, 79, 284 cold-knife, in prospective management of stage IA 1 cervical adenocarcinoma to preserve fertility, preliminary report, 78, 217 loop, and laser vaporization with colposcopy, in cervical dysplasia, 78, 47 persistent/recurrent lesions after, predictive factors, 76, 311 Connective tissue-activating peptide III expression in human cervical epithelium, disappearance with progressive dysplasia, 79, 23 Continent urostomy urolithiasis after formation of, case report and literature review, 77, 330 CT, see Computed tomography Cyclin D1 mutations in uterine papillary serous carcinoma, 77, 439 Cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion, 76, 320 Cyclophosphamide and carboplatin, etoposide, and paclitaxel with G-CSF as first-line therapy in advanced-stage ovarian carcinoma, phase II trial, 77, 271 and cisplatin and paclitaxel with G-CSF, in treatment of primary advanced epithelial ovarian carcinoma, 79, 97 and epidoxorubicin, iv, with intraperitoneal versus iv cisplatin, in advanced epithelial ovarian carcinoma after optimal cytoreduction, randomized trial, 76, 157 ovarian cancer sensitivity, effects of glutathione detoxification system, 76, 362 with secondary hemorrhagic pyelitis, ureteritis, and cystitis, case report and literature review, 76, 223 Cyfra 21-1 serum levels, in squamous cell cervical carcinoma, as predictors of lymph node metastasis or prognosis, 77, 164

Cystitis with ureteritis with hemorrhagic pyelitis, secondary to cyclophosphamide, case report and literature review, 76, 223 Cytokeratin-20 in detection of circulating tumor cells in blood of endometrial carcinoma patients, 78, 352 in detection of micrometastasis by RT-PCR in lymph nodes of endometrial cancer patients, 77, 399 Cytoreduction complete, in epithelial ovarian cancer, effects of tumor site and size, 78, 176 complete salvage, in late recurrent ovarian cancer, 79, 344 surgical, in advanced ovarian cancer, commentary, 78, 269 value in stage IV epithelial ovarian cancer with hepatic metastases, 78, 171 Cytoscopy utility in cervical carcinoma staging, 76, 200 D Dactinomycin and etoposide and methotrexate, in high-risk gestational trophoblastic disease, 78, 28 Depression in epithelial ovarian cancer patients, relationship with health and demographic variables, 78, 302 Dermatofibrosarcoma protuberans of vulva, case report and literature review, 78, 74 DES, see Diethylstilbestrol Desmoplastic small round cell tumor with primary ovarian involvement, case report, 79, 124 Dexamethasone intravenous, with oral ondansetron, antiemetic efficacy in patients receiving carboplatin-based chemotherapy for gynecologic malignancies, 78, 43 Diagnosis histopathologic, ovarian cancer, by referral and registry pathologists at Gilda Radner Familial Ovarian Cancer Registry, comparative study, 78, 166 ovarian lesions, with three-dimensional ultrasound and power Doppler, 76, 28 Diethylstilbestrol intrauterine exposure, relationship to estrogen-associated genital tract cancer, Distinguished Professor Series, 76, 147 Distinguished Professor Series the balanced life: discussion of stress in gynecologic oncology, 76, 301 estrogen-associated genital tract cancer, behavior and relationship to intrauterine DES exposure, 76, 147 DNA hypermethylated, in promoter regions of estrogen receptor ␣ gene in human endometrial diseases, frequency, 76, 89 Docetaxel associated extravasation causing significant delayed tissue injury, case report, 78, 259 in chemoresistant gestational choriocarcinoma, letter to editor, 79, 524 Doxorubicin liposomal in advanced ovarian carcinoma, phase II study, 78, 143 in Pt/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of peritoneum, phase II trial, 78, 369 Dysplasia cervical, atypical nuclei in, identification by fractal analysis, 75, 78; letter to editor, 78, 78; reply, 79 E Editorials are we there yet?, 79, 145 better treatments that cost more: the dilemma, 78, 1

CUMULATIVE SUBJECT INDEX BRCA1: what do we know? what do we think we know? what do we really need to know?, 76, 291 CA 125 in preoperative prediction of optimal resectability in advanced ovarian cancer, 77, 225 cervical adenocarcinoma in situ, margins must be clear, 79, 4 infertility and ovarian cancer, 76, 1 intestinal obstruction in advanced ovarian carcinoma: what does the patient want?, 75, 311; letter to editor, 78, 394; reply, 395 molecular characteristics of cancers: way of the future?, 77, 8 quality counts: value of woman’s perceived quality of life after cervical cancer, 76, 3 role of surgical cytoreduction in stage IV endometrial cancer, 78, 83 in support of second-look surgery in ovarian cancer, 79, 337 transvaginal ultrasound in screening of asymptomatic women for early-stage epithelial ovarian carcinoma, 77, 347 EDR, see Extreme drug resistance assay Education patient, needs among women with ovarian cancer, 77, 357 EGF, see Epidermal growth factor EGF-R, see Epidermal growth factor receptor Elderly radiation therapy for squamous cell cervical carcinoma in, efficacy and toleration, 77, 116 Embolization vascular, of benign granulosa cells, case report, 77, 336 Emesis severe treatment-related, weekly carboplatin administration as strategy for, letter to editor, 78, 265 Endocervical cancer ligand and receptor expression, relationship to p27 Kip1 expression, 78, 106 Endodermal sinus tumors ovarian, diagnosed in pregnancy, case report and literature review, 72, 123; letter to editor, 78, 265; reply, 266 Endometrial adenocarcinoma cultured cells, apoptosis and growth inhibition, induction by antitumor lipoprotein fraction of rice bran, 76, 170 endometrioid type, intratumoral genetic heterogeneity, relationship to metastatic spread, 78, 152 RCAS1 expression in, clinical significance, 79, 424 stage IIIB, clinicopathological study, 78, 203 Endometrial carcinoma advanced or recurrent, paclitaxel and cisplatin in, long-term results of phase II multicenter study, 78, 52 advanced recurrent or persistent, anastrozole therapy in, phase II Gynecologic Oncology Group study, 78, 212 aggressive histologic variants, management at Tom Baker Cancer Centre, 1984 –1994, 77, 248 apoptosis, bcl-2 expression, and proliferation, multiparameter flow cytometric study, 77, 11 atypical clustering, family study with molecular analysis of candidate genes, 77, 18 bcl-XL and bcl-2 expression, 77, 419 cell lines, EGF-induced c-fos expression, inhibition by LHRH analogs, 78, 194 detection of circulating tumor cells by cytokeratin-20 in blood of affected patients, 78, 352 development from endometriosis, hyperestrogenism as risk factor, 79, 18 early stage, cost-effectiveness of treatment in, 74, 208; letter to editor, 76, 142; reply, 142, 74, 208; letter to editor, 77, 483 expression of vascular endothelial growth factor and VEGF receptors, 77, 413 fos and jun expression, 76, 388 gene therapy with herpes simplex thymidine kinase gene, 76, 305 guideline for referral to gynecologic oncologist, rational and benefits, 78, S2

539

initial experiences, Society of Gynecologic Oncologists Outcomes Task Force, 79, 379 intraoperative gross examination in, clinical value, 76, 357 lymph node metastases in, prediction by preoperative ultrasound, 71, 424; letter to editor, 79, 522 lymph node micrometastasis in, detection by cytokeratin-20 RT-PCR, 77, 399 meeting new clinical criteria for hereditary nonpolyposis colorectal carcinoma, case report, 79, 327 with microsatellite instability, absence of PTEN repeat tract mutations in, 79, 101 molecular and cytokinetic pretreatment risk assessment in, 77, 1 myometrial invasion and extracorporal spread, prediction by preoperative computed tomography, 78, 67 node-positive, therapeutic role of para-aortic lymphadenectomy, 76, 348 in obese women, hysterectomy via laparoscopy versus laparotomy in, 78, 329 outcomes of laparoscopic surgery in, 78, 58 papillary serous p27 and cyclin D1 abnormalities, 77, 439 stage I–II clinically and surgically staged, outcomes, comparison with endometrioid carcinoma, 77, 55 presumed early, retrograde seeding of malignant cells during hysterectomy for, 79, 55 recurrence, age as prognostic factor, 79, 79 recurrent, radical radiotherapy for, survival and local control, 77, 66 remaining after term pregnancy following conservative medroxyprogesterone acetate therapy, case report, 79, 129 risk of, impact of tubal sterilization, 79, 482 stage I, high-risk node-negative, local recurrence after postoperative vaginal vault brachytherapy, 79, 490 stage IV, role of surgical cytoreduction, editorial, 78, 83 stage IVB, role of surgical cytoreduction and survival determinants, 78, 85 urokinase-type plasminogen activator, uPAR, and PAI-2, expression, comparison with normal human endometria, 79, 244 Endometrial neoplasia revised nomenclature, histopathological criteria, 76, 287 Endometrial stromal sarcoma low-grade, of ectocervix, after breast cancer therapy, case report, 79, 120 Endometrioid adenocarcinoma uterine, age-specific survival, 79, 86 Endometrioid carcinoma outcomes, comparison with stage I–II clinically and surgically staged papillary serous endometrial carcinoma, 77, 55 Endometriosis development of cancer from, hyperestrogenism as risk factor, 79, 18 ovarian, ovarian carcinoma-associated, clinicopathological and immunohistochemical study, 77, 298 vaginal adenosarcoma arising from, case report, 76, 123 Endometrium benign and malignant tissue, expression of CD35, CD46, CD55 and CD59, 76, 176 diseases, hypermethylated DNA in estrogen receptor ␣ gene promoter regions in, frequency, 76, 89 histopathologic findings in 700 tamoxifen-treated breast cancer patients, 78, 181 hyperplasia, apoptosis as early event in progestin therapy for, 79, 169 long-term transvaginal ultrasonography, in follow-up of tamoxifen-treated postmenopausal breast cancer patients, 74, 222; letter to editor, 76, 423; reply, 423 normal, hyperplastic, and malignant, RCAS1 expression in, clinical significance, 79, 424 power Doppler measurements, diagnostic value in women with postmenopausal bleeding, 77, 243

540

CUMULATIVE SUBJECT INDEX

Epidermal growth factor induced c-fos expression in gynecological cancers, inhibition by LHRH analogs, 78, 194 Epidermal growth factor receptor expression in advanced-stage ovarian carcinoma, correlation with survival, 79, 362 gestational trophoblastic disease, relationship with postmolar tumor development, 77, 389 primary and metastatic epithelial ovarian cancer, 78, 130 Epidoxorubicin and cyclophosphamide, iv, with intraperitoneal versus iv cisplatin, in advanced epithelial ovarian carcinoma after optimal cytoreduction, randomized trial, 76, 157 Estrogen associated genital tract cancer, behavior and relationship to intrauterine DES exposure, Distinguished Professor Series, 76, 147 replacement therapy and cervical adenocarcinoma and squamous cell carcinoma, relationship, 77, 149 hyperestrogenism associated with, as risk factor for cancer development from endometriosis, 79, 18 Estrogen receptor ␣ gene promoter regions, hypermethylated DNA in, frequency in human endometrial diseases, 76, 89 Etoposide and actinomycin D and methotrexate, in high-risk gestational trophoblastic disease, 78, 28 and bleomycin and cisplatin, for ovarian endodermal sinus tumor in pregnancy, case report and literature review, 72, 123; letter to editor, 78, 265; reply, 266 and carboplatin, cyclophosphamide, and paclitaxel with G-CSF as first-line therapy in advanced-stage ovarian carcinoma, phase II trial, 77, 271 Ets expression in ovarian cancer cells lines, correlation to invasive potential, 79, 256 Extravasation docetaxel, with associated significant delayed tissue injury, case report, 78, 259 Extreme drug resistance assay in epithelial ovarian cancer, correlation with response to primary paclitaxel and cisplatin, 70, 392; letter to editor, 76, 143

␣-Fetoprotein production by malignant mixed Mu¨llerian tumor of ovary, case report, 77, 203 Fistulas enterovaginal, resulting from erosion of chemotherapy catheter, case report, 77, 327 radiation-induced, vaginal reconstruction using bladder/rectal walls, 78, 356 retroneovaginal, recurrent, caused by incidental squamous cell carcinoma of neovagina in Mayer–Rokitansky–Ku¨ster–Hauser syndrome, case report, 77, 210 Flow cytometry DNA, in stage IIa cervical carcinoma with cardiac metastasis, case report, 76, 133 Flt-1 expression in endometrial carcinoma, 77, 413 as prognostic indicator in endodermal carcinomas, 76, 33 Flt-3 effects on growth of human ovarian tumors engrafted in SCID mouse, 77, 377 Flt-4 expression in endometrial carcinoma, 77, 413 5-Fluorouracil and cisplatin intraperitoneal therapy in previously treated ovarian carcinoma, phase II study, 77, 433 in preoperative chemoradiation for locally advanced cervical carcinoma, phase I–II trial, 78, 324 Follicle-stimulating hormone growth-promoting effects in ovarian epithelial tumors, effects of luteinizing hormone, 76, 80 Follicle-stimulating hormone receptor mRNA, stability in granulosa cell tumors of ovary, 79, 264 c-fos EGF-induced expression in gynecological cancers, inhibition by LHRH analogs, 78, 194 expression in benign versus malignant human uterine tissue, 76, 388 Fractal analysis in identification of atypical nuclei in dysplastic cervical lesions, 75, 78; letter to editor, 78, 78; reply, 79 FSHR, see Follicle-stimulating hormone receptor G

F Fallopian tube ligation, impact on endometrial cancer risk, 79, 482 Fallopian tube carcinoma germline BCRA2 mutation in affected patient, case report, 77, 319 metachromous, co-occurrence with metachromous carcinoma of vulva, case report, 77, 206 primary, linkage with BRCA1 germline mutations, molecular evidence, 76, 45; letter to editor, 78, 263; response, 264 Pt/paclitaxel-refractory, liposomal doxorubicin in treatment of, phase II trial, 78, 369 recurrent with complete response to topotecan, case report, 76, 128 epithelial, 3-day topotecan therapy every 21 days, phase I trial, 79, 495 Fascia lata preservation of, in complete groin lymphadenectomy in treatment of vulvar carcinoma, 77, 314 Fertility preservation after complete response of squamous cell cervical carcinoma to primary systemic chemotherapy, case report, 77, 213 by cold-knife conization in stage IA 1 cervical adenocarcinoma, preliminary report, 78, 217

G-CSF, see Granulocyte colony stimulating factor Gemcitabine and cisplatin, in advanced, persistent, or recurrent squamous cell carcinoma of cervix, phase II study, 76, 63 in preirradiated recurrent cervical carcinoma, letter to editor, 78, 76 in squamous cell cervical carcinoma, phase II study, 76, 204 Gender issues survey of female gynecologic oncologists: balancing professional and personal life, 79, 309 Gene therapy BCRA1, in ovarian cancer, new generation retroviral vector for, preclinical studies, 79, 471 in endometrial carcinoma, with herpes simplex thymidine kinase gene, 76, 305 HPV16 E7 antisense RNA, effects on CaSki cell tumorigenicity after retrovirus-mediated delivery, 78, 293 Genetic heterogeneity intratumoral, in endometrioid type endometrial adenocarcinoma, relationship to metastatic spread, 78, 152 Germ cell tumors ovarian, malignant, molecular genetic analysis, 77, 283 ovarian and testicular, microsatellite instability in, 79, 38

CUMULATIVE SUBJECT INDEX Gestational trophoblastic disease, see also Choriocarcinoma; Hydatidiform mole; Placental site trophoblastic tumor CA 125 measurement in, 78, 39 expression of epidermal growth factor receptor-related products, relationship with postmolar tumor development, 77, 389 guidelines for referral to gynecologic oncologist, rational and benefits, 78, S13 high-risk, combination chemotherapy with actinomycin D, etoposide, and methotrexate, 78, 28 low-risk, therapeutic trials, guidelines for patient stratification, 78, 92 mode of evacuation and subsequent need for chemotherapy, 78, 309 GLUT-1 expression in borderline and malignant epithelial ovarian tumors, 79, 33 Glutathione detoxification system effects on cisplatin and cyclophosphamide sensitivity in panel of ovarian cancer xenografts, 76, 362 Glycodelin-A expression in uterine cervix, 79, 216 Goserelin induced ovarian ablation, failure in premenopausal women with breast cancer, case reports, 76, 126 Granular cell tumors vulvar, clinical characteristics, histology, and surgical treatment, 77, 310 Granulocyte colony stimulating factor with carboplatin, cyclophosphamide, etoposide, and paclitaxel, as first-line therapy in advanced-stage ovarian carcinoma, phase II trial, 77, 271 with cisplatin– cyclophosphamide–paclitaxel, in treatment of primary advanced epithelial ovarian carcinoma, 79, 97 in possible autocrine stimulation of cervical carcinoma with aggressive tumor growth, case report, 78, 380 Granulosa cells benign, vascular embolization of, case report, 77, 336 Granulosa cell tumors ovarian cellular content of inhibin and p53, 77, 232 loss of alternately spliced LHR mRNA and stability of FSHR mRNA in, 79, 264 Graves’ disease malignant struma ovarii with, case report, 79, 508 Gynecological cancers EGF-induced c-fos expression, inhibition by LHRH analogs, 78, 194 pelvic, intraoperative radiation therapy in, review of 15 cases, 79, 457 recurrent, continent urinary diversion and low-rectal anastomosis in patients undergoing exenterative procedures for, incidence of complications, 78, 208 unconventional cancer therapies in, frequency of use, letter to editor, 79, 336; reply, 336 Gynecologic oncologists female, survey on balancing professional and personal life, 79, 309 guidelines for referral to, in cervical cancer, 78, S9 endometrial cancer, 78, S2 gestational trophoblastic neoplasia, 78, S13 ovarian cancer, 78, S7 pelvic masses, 78, S5 vaginal cancer, 78, S10 vulvar cancer, 78, S11 stress among, Distinguished Professor Series, 76, 301 U.S., job satisfaction among, 76, 163 H Heart metastasis from stage IIa cervical carcinoma, immunohistochemistry, flow cytometry, and virology findings, case report, 76, 133

541

Hemangioma ovarian capillary, presenting as adnexal mass with elevated CA 125, case report, 76, 130 Hemodialysis patients undergoing, elevated serum CA 125 in serosal fluids, 77, 254 Hemorrhage postmenopausal, power Doppler measurements of endometrium in, diagnostic value, 77, 243 Hepatitis C and ascites, extreme elevation of CA 125 associated with, letter to editor, 70, 441; letter to editor; 76, 141; reply, 76, 141 Hepatocyte growth factor promotion of in vitro scattering and morphogenesis in human cervical carcinoma cells, 78, 158 HER2 protein expression in primary and metastatic epithelial ovarian cancer, 78, 130 Hereditary breast– ovarian cancer syndrome BRCA1 and BRCA2 mutation carriers with, ovarian histology, comparison with noncarrier kindreds, 78, 278 uterine papillary serous adenocarcinoma as manifestation of, 79, 477 Histiocytosis Langerhans’ cell, on vulva, case report, 78, 251 Histopathology clear cell, and lymph node metastasis, prognostic significance in ovarian carcinoma limited to pelvis, 79, 251 endometrial, in 700 tamoxifen-treated breast cancer patients, 78, 181 ovarian cancer, diagnoses by referral and registry pathologists at Gilda Radner Familial Ovarian Cancer Registry, comparative study, 78, 166 prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers, comparison with noncarriers in hereditary breast cancer syndrome kindreds, 78, 278 Hormone replacement therapy, see Estrogen, replacement therapy HPV, see Human papillomavirus Human immunodeficiency virus cervical intraepithelial neoplasia in seropositive and seronegative women, E-cadherin and CD44 expression, correlation with HPV status, 76, 56 epithelial ovarian carcinoma in infected patient, treatment with paclitaxel and cisplatin, case report, 76, 118 increase in lymphocyte infiltrates in CIN lesions in affected patients, 76, 315 infection, and invasive cervical cancer, in South Africa, 77, 460 rapid progression of primary squamous cell vaginal carcinoma in young infected woman, case report, 78, 380 Human papillomavirus correlation with E-cadherin and CD44 expression in cervical intraepithelial neoplasia, in HIV positive and negative women, 76, 56 E6/E7, modulation by RU486 in dexamethasone treated cervical carcinoma cells through, effects on radiosensitivity and apoptosis, 77, 177 HPV 16 E6, differential distribution of sequence variations in cervical cancer, 79, 11 E7 antisense RNA, effects on CaSki cell tumorigenicity after retrovirusmediated delivery, 78, 293 infection persistence after therapeutic conization for CIN III, as indicator of recurrence risk, 79, 294 in premalignant disease of cervix, possible protective role of adenoassociated virus 2 infection, 78, 342 in stage IIa cervical carcinoma with cardiac metastasis, case report, 76, 133 oncogenic, association with telomerase activity in pap smear-negative exfoliated cervical cells, 77, 394 subtypes, analysis in lower genital tract neoplasms of female renal transplant recipients, 79, 220

542

CUMULATIVE SUBJECT INDEX

testing by hybrid capture, role in triage of women with repeated abnormal Papanicolaou smears before colposcopy referral, 79, 177 well-differentiated villoglandular cervical adenocarcinoma positive for, case report and literature review, 77, 473 Hydatidiform mole complete, and coexisting viable fetus, case report and literature review, 77, 197; letter to editor, 79, 525; reply, 525 recurrent, patient characteristics, 78, 288 Hypercalcemia due to parathyroid hormone-related protein produced by clear cell ovarian adenocarcinoma, case report, 76, 218 humoral, from mature cystic teratoma, PTH-rp in squamous cell carcinoma arising from, immunohistochemical detection, case report, 79, 504 Hyperestrogenism as risk factor for cancer development from endometriosis, 79, 18 Hyperplasia florid endocervical glandular, with intestinal and pyloric gland metaplasia, as benign mimic of adenoma malignum, case report, 74, 504; letter to editor, 77, 341; reply, 342 Hysterectomy and adjuvant radiotherapy, cost-effectiveness in early stage endometrial carcinoma, 74, 208; letter to editor, 76, 142; reply, 142 after conization for CIN III, predictive factors for residual disease, 79, 284 for cervical adenocarcinoma in situ, recurrence of invasive adenocarcinoma following, case report, 77, 334 for presumed early endometrial carcinoma, retrograde seeding of malignant cells during, 79, 55 prevalence, and effect on uterine cancer incidence rates, letter to editor, 79, 337 radical anatomic evaluation of parametrial dissection, 77, 155 in bulky barrel-shaped lesion of cervix, 78, 313 in cervical carcinoma, intraoperative lymphatic mapping in patients undergoing, 79, 238 exclusion of small intestine from radiation field with pelvic displacement prothesis, 79, 438 frequency of abandonment and patient outcomes, Gynecologic Oncology Group Study, 79, 350 in high-risk cervical carcinoma, adjuvant chemotherapy or radiotherapy, or observation following, randomized prospective trial, 73, 196; letter to editor, 77, 340; reply, 341 surgical stapling technique for, survival, recurrence, and late complications, 79, 281 type III, motor innervation of bladder in, identification and preservation, 79, 154 vaginal, combined with laparoscopy, in early-stage cervical cancer, 79, 59 vaginal, laparoscopically assisted, outcomes in endometrial cancer, 78, 58 via laparoscopy versus laparotomy in obese women with endometrial carcinoma, 78, 329

I Ifosfamide with cisplatin in treatment of uterine carcinosarcoma, phase III trial, 79, 147 and platinum, versus carboplatin/paclitaxel, in malignant mixed Mu¨llerian tumor of ovary, 79, 196 single-agent, in treatment of uterine sarcoma, safety and efficacy, 78, 221 IL, see Interleukins Immunohistochemistry stage IIa cervical carcinoma with cardiac metastasis, case report, 76, 133 Indiana pouch urolithiasis after formation of, case report and literature review, 77, 330 Indole-3-carbinol in cervical intraepithelial neoplasia, placebo-controlled trial, 78, 123

Infertility and ovarian cancer, editorial, 76, 1 Inhibin cellular content in ovarian granulosa cell tumors, 77, 232 Interleukins IL-6, in possible autocrine stimulation of cervical carcinoma with aggressive tumor growth, case report, 78, 380 IL-12, NK cell activity in presence of, in cervical cancer, as prognostic assay for neoadjuvant chemotherapy, 78, 318 Intestinal obstruction in advanced ovarian carcinoma, management options and patient desires, editorial, 75, 311; letter to editor, 78, 394; reply, 395 Intestine jejunal adenocarcinoma presenting as ovarian carcinoma, case report, 78, 255 Italy central, risk factors for ovarian carcinoma in, 79, 50 J Jejunal adenocarcinoma presenting as ovarian carcinoma, case report, 78, 255 Job satisfaction among U.S. gynecological oncologists, 76, 163 female gynecologic oncologists: survey on balancing professional and personal life, 79, 309 jun expression in benign versus malignant human uterine tissue, 76, 388 K KAI1 down regulation and lack of mutation in ovarian carcinoma, 78, 10 KDR expression in endometrial carcinoma, 77, 413 KDR/flk-1 as prognostic indicator in endodermal carcinomas, 76, 33 Ki-67 expression in vulvar carcinoma and vulvar intraepithelial neoplasia III, correlation with clinical prognostic factors, 76, 51 as prognostic factor for radiotherapy in cervical cancer, 79, 300 Kidney transplants, lower genital tract neoplasms of female recipients of, human papillomavirus subtypes in, analysis, 79, 220 L Langerhans’ cell histiocytosis of vulva, case report, 78, 251 Laparoscopy in assessment of sentinel lymph node in early-stage cervical carcinoma, 79, 411 assisted vaginal hysterectomy, outcomes in endometrial cancer, 78, 58 combined with radical vaginal surgery, in early-stage cervical cancer, 79, 59 versus laparotomy, for hysterectomy in obese women with endometrial carcinoma, 78, 329 in left extraperitoneal para-aortic lymphadenectomy for cervical cancer, technical development and results, 77, 87 port-site metastasis following early stage cervical adenocarcinoma with negative lymph nodes, case report, 75, 155; letter to editor, 77, 339; reply, 339 stage IB squamous cell cervical carcinoma with negative lymph nodes, case report, 79, 324 spread of ovarian cancer following, report of eight cases, 75, 387; letter to editor, 78, 77; reply, 78

543

CUMULATIVE SUBJECT INDEX Laparotomy versus laparoscopy, for hysterectomy in obese women with endometrial carcinoma, 78, 329 Laser vaporization with colposcopy and loop conization, in cervical dysplasia, 78, 47 Leupin/SCCA-2 immunoreactivity in cervical carcinoma, implications for tumor marker detection, 78, 62 LHRH, see Luteinizing hormone-releasing hormone Lichen sclerosus allelic imbalance and microsatellite instability phenotype in, 77, 171 Liver metastases from stage IV epithelial ovarian cancer, optimal cytoreductive surgery as independent prognostic indicator, 78, 171 LOH, see Loss of heterozygosity Loop conization with colposcopy and laser vaporization, in cervical dysplasia, 78, 47 Loss of heterozygosity chromosome 4, in invasive cervical carcinoma among histologic variants, 79, 90 WT1 gene, in papillary serous carcinoma of peritoneum, 76, 369 Xp22.2-3, associated with BRCA1 germline mutation in ovarian cancer, 76, 418 Luteinizing hormone effects on growth promotion by follicle-stimulating hormone in ovarian epithelial tumors, 76, 80 Luteinizing hormone receptor alternately spliced mRNA, loss in granulosa cell tumors of ovary, 79, 264 mRNA expression, decrease in epithelial ovarian carcinoma, 79, 158 Luteinizing hormone-releasing hormone agonistic and antagonistic analogs, effects on EGF-induced c-fos expression in gynecological cancers, 78, 194 Lymphadenectomy complete groin, with preservation of fascia lata, in vulvar carcinoma, 77, 314 para-aortic left extraperitoneal laparoscopic, in cervical cancer, technical development and results, 77, 87 role in node-positive endometrial cancer, 76, 348 Lymphatic mapping intraoperative, in cervical carcinoma patients undergoing radical hysterectomy, 79, 238 Lymph nodes bilateral pelvic, metastases from stage IA cervical adenocarcinoma, case report, 77, 467 inguinal, ultrasound assessment of status in vulvar cancer, 77, 93 metastasis and clear cell histology in ovarian carcinoma limited to pelvis, prognostic significance, 79, 251 in endometrial cancer, prediction by preoperative ultrasound, 71, 424; letter to editor, 79, 522 in squamous cell cervical carcinoma, serum Cyfra 21-1, SCC-Ag, and TPA levels as predictors, 77, 164 in stage IB, IIA, and IIB cervical carcinoma, risk factors after radical hysterectomy and postoperative pelvic irradiation, 77, 305 in stage I epithelial ovarian cancer, 79, 305 micrometastasis in endometrial carcinoma, detection by cytokeratin-20 RTPCR, 77, 399 para-aortic, cervical carcinoma metastatic to, survival after extended field irradiation for, 79, 399 para-aortic and pelvic, benign Mu¨llerian inclusions in, incidence and distribution, 78, 242

sentinel dissection, and ultrastaging, in squamous cell vulvar carcinoma, 76, 40; letter to editor, 77, 484; reply, 485 laparoscopic assessment in early-stage cervical carcinoma, 79, 411 Lymphocytes infiltrates in CIN lesions in HIV positive patients, 76, 315 M Macrophage colony-stimulating factor and squamous cell carcinoma antigen, as marker for squamous cell carcinoma arising in mature cystic teratoma of ovary, 77, 405 MAGE-4 protein serum levels, in ovarian cancer patients, 76, 336 Magnetic resonance imaging in classification of asymptomatic adnexal masses, 77, 454 in invasive cervical carcinoma, effects on therapeutic decisions, 79, 485 in stage IA cervical carcinoma, correlation with invasive cervical biopsy, 79, 451 Malignant struma ovarii with Graves’ disease, case report, 79, 508 Mammary epithelial cells with BRCA1 185delAG mutation, establishment and characterization, 77, 121 Matrix metalloproteinases expression in cyst fluids of ovarian mucinous neoplasms, 78, 106 expression in ovarian cancer cells lines, correlation to invasive potential, 79, 256 MMP-9, protein and mRNA expression in epithelial ovarian tumors, 77, 369 Mature cystic ovarian teratoma squamous cell carcinoma arising in, M-CSF and squamous cell carcinoma antigen as diagnostic markers, 77, 405 Mayer–Rokitansky–Ku¨ster–Hauser syndrome incidental squamous cell carcinoma of neovagina causing recurrent retroneovaginal fistula in, case report, 77, 210 M-CSF, see Macrophage colony-stimulating factor mdm-2 expression in Mu¨llerian serous carcinomas, 79, 430 MDR1 protein expression in primary and metastatic epithelial ovarian cancer, 78, 130 Medroxyprogesterone acetate treatment for endometrial carcinoma during pregnancy, residual tumor remaining after delivery, case report, 79, 129 Metachromous carcinoma of vulva and Fallopian tube, case report, 77, 206 Metaplasia intestinal and pyloric gland, with florid endocervical glandular metaplasia, as benign mimic of adenoma malignum, case report, 74, 504; letter to editor, 77, 341; reply, 342 Metastases in advanced-stage ovarian carcinoma, correlation with carbohydrate antigen expression, 77, 35 cardiac from cloacogenic carcinoma of vagina, case report and review of gynecologic malignancies with cardiac metastasis, 76, 208 from stage IIa cervical carcinoma, immunohistochemistry, flow cytometry, and virology findings, case report, 76, 133 in cervical cancer, and cyclooxygenase-2 expression, 76, 320 choroidal, as initial symptom of recurrence of endometrioid ovarian adenocarcinoma, case report, 77, 219 in endometrial carcinoma detection of circulating tumor cells by cytokeratin-20 in blood of affected patients, 78, 352 prediction by preoperative computed tomography, 78, 67

544

CUMULATIVE SUBJECT INDEX

endometrioid type endometrial adenocarcinoma, relationship to intratumoral genetic heterogeneity, 78, 152 extrauterine, from uterine Mu¨llerian adenosarcoma, management of, case report, 77, 464 hepatic, from stage IV epithelial ovarian cancer, optimal cytoreductive surgery as independent prognostic indicator, 78, 171 lymph node bilateral pelvic, from stage IA cervical adenocarcinoma, case report, 77, 467 and clear cell histology in ovarian carcinoma limited to pelvis, prognostic significance, 79, 251 in endometrial cancer, prediction by preoperative ultrasound, 71, 424; letter to editor, 79, 522 para-aortic, from cervical carcinoma, survival after extended field irradiation for, 79, 399 risk in stage IA squamous cell carcinoma of vulva, 76, 24 in squamous cell cervical carcinoma, serum Cyfra 21-1, SCC-Ag, and TPA levels as predictors, 77, 164 in stage I epithelial ovarian cancer, 79, 305 port-site after laparoscopy for early stage cervical adenocarcinoma with negative lymph nodes, case report, 75, 155; letter to editor, 77, 339; reply, 339 stage IB squamous cell cervical carcinoma with negative lymph nodes, case report, 79, 324 skin, hematogenous, from cervical cancer at primary presentation, 76, 416 uterine, from heterologous metaplastic breast carcinoma simulating a primary uterine malignancy, case report, 77, 216 Methotrexate and actinomycin D and etoposide, in high-risk gestational trophoblastic disease, 78, 28 MIB-1 labeling index as prognostic factor in stage IB squamous cell carcinoma of cervix, 76, 97 proliferation index assessed with, as prognostic factor in radiation therapy for cervical cancer, 79, 300 Micrometastasis lymph node, in endometrial carcinoma, detection by cytokeratin-20 RTPCR, 77, 399 Microsatellite instability endometrial carcinoma with, absence of PTEN repeat tract mutations in, 79, 101 in gynecologic malignancies, atypical clustering, family study with molecular analysis of candidate genes, 77, 18 as late event in cervical carcinoma carcinogenesis, 79, 201 in lichen sclerosus, hyperplasia and intraepithelial neoplasia of vulva, 77, 171 in ovarian and testicular germ cell tumors, 79, 38 Mifepristone in refractory ovarian cancer, phase II study, 77, 429 MMAC1 mutational analysis in cervical carcinoma, 76, 193 MMP, see Matrix metalloproteinases MRI, see Magnetic resonance imaging Mu¨llerian inclusions benign, in pelvic and para-aortic lymph nodes, incidence and distribution, 78, 242 Mu¨llerian tumors adenosarcoma of uterus with extrauterine metastatic deposits, management of, case report, 77, 464 malignant mixed ovarian carboplatin/paclitaxel versus ifosfamide/platinum chemotherapy in, 79, 196 ␣-fetoprotein production by, case report, 77, 203

serous, tumor suppressor gene, cell surface adhesion molecule and multidrug resistance in, clinical divergence without immunophenotypic differences, 79, 430 Mutational analysis PTEN/MMAC1 tumor suppressor gene in cervical carcinoma, 76, 193 Mutations BRCA1 185delAG, mammary epithelial cells with, establishment and characterization, 77, 121 germline association with Xp22.2-3 LOH, 76, 418 linkage with primary cancer of the Fallopian tube, molecular evidence, 76, 45; letter to editor, 78, 263; response, 264 BRCA1–2, in patients with double primary tumors of breast and ovary, 79, 74 BRCA2 germline, in ovarian carcinosarcoma patient, evidence for monoclonal origin, case report, 76, 226 chromosome 4 deletions, in invasive cervical carcinoma among histologic variants, 79, 90 PTEN, repeat tract, absence in endometrial cancers with microsatellite instability, 79, 101 ras, in papillary serous carcinoma of the peritoneum, 77, 105 Rb, in uterine papillary serous carcinoma, 77, 439 Myocutaneous flaps anterolateral thigh vastus lateralis, for vulvar reconstruction after radical vulvectomy, case report, 78, 391 N National Cancer Data Base/Surveillance Epidemiology and End Results potential insensitive-measure bias in, 77, 450 Natural killer cells activity in presence of IL-12, in cervical cancer, as prognostic assay for neoadjuvant chemotherapy, 78, 318 response to human ovarian cancer xenografts in SCID mouse, effects of Flt-3 ligand, 77, 377 Neovagina incidental squamous cell carcinoma, recurrent retroneovaginal fistula caused by, in Mayer–Rokitansky–Ku¨ster–Hauser syndrome, case report, 77, 210 NK cells, see Natural killer cells Nomenclature endometrial neoplasia, histopathological criteria, 76, 287 O Obesity hyperestrogenism associated with, as risk factor for cancer development from endometriosis, 79, 18 hysterectomy via laparoscopy versus laparotomy in, for endometrial carcinoma, 78, 329 Oncologists, see Gynecologic oncologists Ondansetron oral, plus iv dexamethasone, antiemetic efficacy in patients receiving carboplatin-based chemotherapy for gynecologic malignancies, 78, 43 Ovarian ablation goserelin-induced, failure in premenopausal women with breast cancer, case reports, 76, 126 Ovarian adenocarcinoma clear cell, parathyroid hormone-related protein produced by, associated hypercalcemia, case report, 76, 218 endometrioid, choroidal metastasis presenting as initial symptom of recurrence, case report, 77, 219 Ovarian capillary hemangioma presenting as adnexal mass with elevated CA 125, case report, 76, 130

CUMULATIVE SUBJECT INDEX Ovarian carcinoid tumor management of primary and recurrent tumors, case report, 76, 112 Ovarian carcinoma advanced-stage CA 125 in preoperative prediction of optimal resectability, 77, 227 editorial, 77, 225 E-cadherin complex protein expression in, correlation with survival, 79, 362 carbohydrate antigen expression, correlation with metastasis, 77, 35 carboplatin, cyclophosphamide, etoposide, and paclitaxel with G-CSF as first-line therapy, phase II trial, 77, 271 liposomal doxorubicin in treatment of, phase II study, 78, 143 primary appendiceal malignancy mimicking, case reports, 78, 388 CA 125 serum levels, effects of paclitaxel, 76, 326 CA 125 and TPS serum levels after three chemotherapy courses for, prognostic significance, 79, 444 carboplatin/cisplatin intraperitoneal administration for, complications, 79, 420 cell lines apoptosis in, induction by 2-5A antisense directed against telomerase RNA, 76, 183 constitutive activation of Stat 3, 79, 67 EGF-induced c-fos expression, inhibition by LHRH analogs, 78, 194 expression of matrix metalloproteinase and Ets family transcriptional factors, correlation to invasive potential, 79, 256 cisplatin and 5-FU intraperitoneal therapy in previously treated patients, phase II study, 77, 433 clear cell, CD44 isoforms in, 79, 187 decline in CA 125 levels in patient with progression of measurable disease, case report, 77, 321 docetaxel extravasation causing significant delayed tissue injury in, case report, 78, 259 early-stage, lymph node metastasis and clear cell histology, prognostic significance, 79, 251 epithelial advanced-stage CA 125 serum levels, effects of topotecan, 77, 383 intraperitoneal versus iv cisplatin with iv cyclophosphamide and epidoxorubicin after optimal cytoreduction, randomized trial, 76, 157 apolipoprotein D expression and clinical significance, 76, 340 decrease of luteinizing hormone receptor mRNA expression in, 79, 158 depression, anxiety, and quality of life in affected patients, relationship with health and demographic variables, 78, 302 differential expression of MMP-9 and TIMP-1 protein and mRNA, 77, 369 early-stage, transvaginal ultrasound in screening of asymptomatic women, 77, 350 editorial, 77, 347 EDR assay, correlation with response to primary paclitaxel and cisplatin, 70, 392; letter to editor, 76, 143 human, engrafted in SCID mouse, effects of flt-3 ligand, 77, 377 invasive, founder BRCA1 and 2 mutations among Ashkenazi patients, 78, 148 KAI1 metastasis suppressor gene, down regulation and lack of mutation in, 78, 10 long-term results and prognostic factors, 78, 21 p21 protein expression, association with prolonged survival, 77, 237 p53 and bcl-2 expression, prognostic value at median follow-up of 60 months, 77, 278 paclitaxel and cisplatin therapy in HIV-infected patient, case report, 76, 118 with positive second look, intraperitoneal cisplatin and iv paclitaxel in treatment of, 79, 28

545

primary advanced, cisplatin– cyclophosphamide–paclitaxel with G-CSF in treatment of, 79, 97 primary and metastatic, p53, HER2, EGF-R, MDR1, and CD31 expression, 78, 130 Pt-resistant, chemoresponse prediction by ATP cell viability assay, 76, 405 recurrent 3-day topotecan therapy every 21 days for, phase I trial, 79, 495 single-agent paclitaxel in treatment of after initial therapy with paclitaxel and platinum, 79, 211 SPARC and VEGF immunoreactivity, 78, 336 stage I, lymph node metastasis in, 79, 305 stage II and III, survival after complete cytoreduction, effects of tumor size and site, 78, 176 stage III, drug response, correlation with ATP tumorchemosensitivity assay, 77, 258 stage IV, with hepatic metastases, optimal cytoreductive surgery as independent prognostic indicator, 78, 171 thymidine phosphorylase expression, correlation with angiogenesis, apoptosis, and ultrasound-derived peak systolic velocity, 77, 26 in female-to-male transsexuals, case report, 76, 413 FSH-induced growth promotion, effects of luteinizing hormone, 76, 80 guidelines for referral to gynecologic oncologist, rational and benefits, 78, S7 histopathology, diagnoses by referral and registry pathologists at Gilda Radner Familial Ovarian Cancer Registry, comparative study, 78, 166 and infertility, editorial, 76, 1 intraperitoneal chemotherapy, real-time ultrasonographically guided transvaginal instillation, case report, 79, 332 jejunal adenocarcinoma presenting as, case report, 78, 255 long-term survivor, prolonged and aggressive treatment with Pt-based chemotherapy and surgery, case report, 78, 261 MAGE-4 protein serum levels in, prognostic value, 76, 336 ovarian endometriosis associated with, clinicopathological and immunohistochemical study, 77, 298 papillary serous, tumor suppressor gene, cell surface adhesion molecule and multidrug resistance in, clinical divergence without immunophenotypic differences, 79, 430 patients, information needs and decisional preferences, 77, 357 patients with previous history of primary breast cancer, clinical characteristics and BRCA1–2 mutation status, 79, 74 platinum- and paclitaxel-resistant liposomal doxorubicin in treatment of, phase II trial, 78, 369 topotecan administered on 3-day schedule, phase II evaluation, 79, 116 weekly 72-hour topotecan infusion in, phase II and pharmacokinetic study, 78, 228 platinum-refractory, CI-958 in treatment of, Gynecologic Oncology Group phase II trial, 79, 463 recurrent efficacy and hematologic toxicity of salvage chemotherapy after PBSCTsupported high dose chemotherapy, 77, 48 late, complete salvage surgical cytoreduction in, 79, 344 potentially Pt-sensitive, 24-h continuous infusion of topotecan in, phase II Gynecologic Oncology Group study, 77, 112 pretherapeutic tetranectin and CA 125 in, prognostic value, 79, 416 refractory, mifepristone therapy in, phase II study, 77, 429 risk factors for, in central Italy, 79, 50 second-look surgery in, opinion in support of, editorial, 79, 337 splenectomy and surgical cytoreduction in, 77, 362 sporadic, BRCA1 expression, 76, 294 spread of, following laparoscopic surgery, report of eight cases, 75, 387; letter to editor, 78, 77; reply, 78

546

CUMULATIVE SUBJECT INDEX

squamous cell arising from mature cystic teratoma causing humoral hypercalcemia of malignancy, immunohistochemical detection of PTH-rp in, case report, 79, 504 rapidly growing, successful control by weekly paclitaxel– carboplatin administration, case report, 79, 515 Stockholm Screening Study on, long-term follow-up, 79, 466 T-cell factor–␤-catenin pathway activation in, 77, 97 xenografts growth and anticancer drug efficacy in vivo, SEAP as surrogate marker, 78, 373 intraperitoneal photoimmunotherapy in nude mice using charged photoimmunoconjugates, 76, 397 in panel for drug screening and determination of glutathione detoxification system role, 76, 362 Ovarian carcinosarcoma in patient with germline BRCA2 mutation, evidence for monoclonal origin, case report, 76, 226 Ovarian dysgerminoma pregnancy in women with chromosome Y after removal of, case report, 79, 519 Ovarian teratoma benign cystic, adenocarcinoma of GI epithelial origin arising from, case report, 70, 418; letter to editor, 77, 478 mature cystic, squamous cell carcinoma arising in, M-CSF and squamous cell carcinoma antigen as diagnostic markers, 77, 405 Ovarian tumors borderline advanced-stage, surgical response to cisplatin and paclitaxel, letter to editor, 77, 343 CA 19-9, CA 125, and CEA as markers of recurrence, 78, 16 malignant transformation of, role of GLUT-1 expression, 79, 33 surgical management, survey of Society of Gynecologic Oncologists, 78, 7 endodermal sinus, diagnosed in pregnancy, case report and literature review, 72, 123; letter to editor, 78, 265; reply, 266 epithelial differential expression of MMP-9 and TIMP-1 protein and mRNA, 77, 369 inverse expression of cdk4 and p16 in, 79, 230 germ cell malignant, molecular genetic analysis, 77, 283 microsatellite instability in, 79, 38 granulosa cell cellular content of inhibin and p53, 77, 232 loss of alternately spliced LHR mRNA and stability of FSHR mRNA in, 79, 264 malignant mixed Mu¨llerian carboplatin/paclitaxel versus ifosfamide/platinum chemotherapy in, 79, 196 ␣-fetoprotein production by, case report, 77, 203 mucinous, MMP and TIMP expression in cyst fluids, 78, 106 primary desmoplastic small round cell tumor, case report, 79, 124 signet ring stromal tumor, occurrence with Brenner tumor, case report, 77, 323 Ovary lesions, three-dimensional ultrasound and power Doppler in diagnosis, 76, 28 postmenopausal, transvaginal ultrasound assessment of, reproducibility, 77, 289 prophylactically removed from BRCA1 and BRCA2 mutation carriers, histology, comparison with noncarriers in hereditary breast cancer syndrome kindreds, 78, 278 volume, relationship to age, 77, 410

P p16 mutations in uterine papillary serous carcinoma, 77, 439 p16 protein and cdk4, inverse expression in epithelial ovarian tumors, 79, 230 p21 mutations in uterine papillary serous carcinoma, 77, 439 p21 protein expression in epithelial ovarian carcinoma, association with prolonged survival, 77, 237 p27 Kip1 expression in endocervical cancer, relationship to TGF-␤ ligand and receptor expression, 78, 106 p53 cellular content in ovarian granulosa cell tumors, 77, 232 expression in cervical carcinomas and premalignant lesions, clinical significance, 77, 129 epithelial ovarian carcinoma association with p21 protein expression, 77, 237 prognostic value at median follow-up of 60 months, 77, 278 mutations in uterine papillary serous carcinoma, 77, 439 p53 protein expression in Mu¨llerian serous carcinomas, 79, 430 expression in primary and metastatic epithelial ovarian cancer, 78, 130 Paclitaxel and carboplatin and cyclophosphamide and etoposide, with G-CSF as first-line therapy in advanced-stage ovarian carcinoma, phase II trial, 77, 271 versus ifosfamide/platinum, in malignant mixed Mu¨llerian tumor of ovary, 79, 196 rapidly growing squamous cell ovarian carcinoma successfully controlled by weekly administration, case report, 79, 515 and cisplatin in advanced or recurrent endometrial carcinoma, long-term results of phase II multicenter study, 78, 52 in advanced-stage borderline ovarian tumors, surgical response, letter to editor, 77, 343 and cyclophosphamide, with G-CSF, in treatment of primary advanced epithelial ovarian carcinoma, 79, 97 in epithelial ovarian carcinoma in HIV-infected patient, case report, 76, 118 primary, response in epithelial ovarian cancer, correlation with EDR assay, 70, 392; letter to editor, 76, 143 effects on CA 125 serum levels in ovarian cancer patients, 76, 326 efficacy in ovarian carcinoma xenografts, SEAP as surrogate marker in vivo, 78, 373 iv, and intraperitoneal cisplatin, in treatment of epithelial ovarian carcinoma with positive second look, 79, 28 single-agent, in treatment of relapsed ovarian carcinoma after paclitaxel and platinum as initial therapy, 79, 211 Paget’s disease of vulva pathology, pattern of involvement and prognosis, 77, 183 PAI-2, see Plasminogen activator inhibitor type 2 Papanicolaou smears atypical atrophic, proliferative activity in, measurement, 79, 225 negative exfoliated cervical cells, telomerase activity, association with lesions and oncogenic human papillomavirus, 77, 394 repeated abnormal, role of HPV testing by hybrid capture in triage of women before colposcopy referral, 79, 177 routine, primary peritoneal carcinoma presentation on, case report, 78, 71

CUMULATIVE SUBJECT INDEX ThinPrep atypical glandular cells of undetermined significance on, significance, 78, 245 atypical squamous cells of undetermined significance on, significance, 79, 44 Papillary serous adenocarcinoma peritoneal genetic alterations of WT1 gene in, 76, 369 ras gene activation and mutation in, 77, 105 uterine as manifestation of hereditary breast– ovarian cancer syndrome, 79, 477 p27 and cyclin D1 abnormalities, 77, 439 Parathyroid hormone related protein produced by clear cell ovarian adenocarcinoma, associated hypercalcemia, case report, 76, 218 Parathyroid hormone-related protein immunohistochemical detection in squamous cell carcinoma arising from mature cystic teratoma causing humoral hypercalcemia of malignancy, case report, 79, 504 PBSCT, see Peripheral blood stem cell transplantation Pelvic exenteration vaginal and pelvic floor reconstruction at time of, morbidity study, 77, 293 Pelvic masses cystic, primary vaginal squamous cell carcinoma presenting as, case report, 76, 213 and fever, in patient with elevated CA 125, diagnosis as tuberculosis peritonitis, case report, 77, 471 guidelines for referral to gynecologic oncologist, rational and benefits, 78, S5 Pentoxifylline and cisplatin, in advanced/recurrent squamous cell carcinoma of the cervix, phase II trial, 79, 64 Pericardium serosal fluids in, elevated serum CA 125 levels in hemodialysis patients with, 77, 254 Peripheral blood stem cell transplantation supported high-dose chemotherapy, subsequent salvage chemotherapy, efficacy and hematologic toxicity in recurrent ovarian cancer, 77, 48 Peritoneal carcinoma epithelial, recurrent, 3-day topotecan therapy every 21 days for, phase I trial, 79, 495 papillary serous genetic alterations of WT1 gene in, 76, 369 ras gene activation and mutation in, 77, 105 primary presentation on routine Papanicolaou smear, case report, 78, 71 Pt/paclitaxel-refractory, liposomal doxorubicin in treatment of, phase II trial, 78, 369 recurrent serous, detection with whole-body PET with (fluorine-18)-2deoxyglucose, 77, 44 Peritoneum serosal fluids of hemodialysis patients, serum CA 125 levels, 77, 254 PET, see Positron emission tomography P-glycoprotein expression in Mu¨llerian serous carcinomas, 79, 430 Photoimmunoconjugates charged, in intraperitoneal photoimmunotherapy of ovarian carcinoma xenografts in nude mice, 76, 397 Photoimmunotherapy intraperitoneal, of ovarian carcinoma xenografts in nude mice using charged photoimmunoconjugates, 76, 397 Placental site trophoblastic tumor recurrent, prolonged remission after chemotherapy, case report, 76, 115

547

Plasminogen activator urokinase-type, and uPAR and PAI-2, mRNA expression in normal human endometria and endometrial carcinoma, 79, 244 Plasminogen activator inhibitor type 2 urokinase-type PA, and uPAR, mRNA expression in normal human endometria and endometrial carcinoma, 79, 244 Platinum high- versus standard-dose, in advanced ovarian carcinoma, randomized trial, 78, 361 and ifosfamide, versus carboplatin/paclitaxel, in malignant mixed Mu¨llerian tumor of ovary, 79, 196 recurrent ovarian cancer potentially sensitive to, 24-h continuous infusion of topotecan in, phase II Gynecologic Oncology Group study, 77, 112 Pleura serosal fluids in, elevated serum CA 125 levels in hemodialysis patients with, 77, 254 Poems “Same Again,” letter to editor, 76, 139 “We Would Be To,” letter to editor, 76, 140 Polymerase chain reaction, see Reverse transcription polymerase chain reaction Port-site metastases after laparoscopy for early stage cervical adenocarcinoma with negative lymph nodes, case report, 75, 155; letter to editor, 77, 339; reply, 339 following stage IB squamous cell cervical carcinoma with negative lymph nodes, case report, 79, 324 Positron emission tomography in classification of asymptomatic adnexal masses, 77, 454 whole-body, with (fluorine-18)-2-deoxyglucose, in detection of recurrent primary serous peritoneal carcinoma, 77, 44 Postmenopause bleeding, power Doppler measurements of endometrium in, diagnostic value, 77, 243 ovaries, transvaginal ultrasound assessment of, reproducibility, 77, 289 Power Doppler measurements of endometrium in women with postmenopausal bleeding, diagnostic value, 77, 243 Pregnancy after failure of goserelin ovarian ablation in premenopausal women with breast cancer, case report, 76, 126 chemotherapy for endodermal sinus tumor during, case report and literature review, 72, 123; letter to editor, 78, 265; reply, 266 term, endometrial carcinoma remaining after conservative medroxyprogesterone acetate therapy, case report, 79, 129 with viable fetus coexisting with complete hydatidiform mole, case report and literature review, 77, 197; letter to editor, 79, 525; reply, 525 in women with chromosome Y after removal of ovarian dysgerminoma, case report, 79, 519 Proctitis radiation, relationship with high-dose intracavitary brachytherapy and high external parametrial radiation, in cervical carcinoma, 79, 406 Progestin therapy for endometrial hyperplasia, apoptosis as early event in, 79, 169 Prognostic factors age, for recurrence of endometrial carcinoma, 79, 79 apolipoprotein D expression in epithelial ovarian carcinoma, 76, 3407 CA 19-9, CA 125, and CEA in borderline ovarian tumors, 78, 16 CA 125 and TPS serum levels after three chemotherapy courses in ovarian cancer patients, 79, 444 E-cadherin complex protein expression in advanced-stage ovarian carcinoma, 79, 362 carbohydrate antigen expression in advanced-stage ovarian carcinoma, 77, 35

548

CUMULATIVE SUBJECT INDEX

CD31, EGF-R, HER2, MDR1, and p53 expression, in primary and metastatic epithelial ovarian cancer, 78, 130 CD44 expression in cervical squamous neoplasia, 76, 73 cdk4 and p16 expression in epithelial ovarian tumors, 79, 230 CEA, TPA, and SCC-Ag, in low-risk stage IB-IIA squamous cell carcinoma of cervix, 76, 103 CIN persistence and recurrence after conization, 76, 311 clinical, vulvar carcinoma and vulvar intraepithelial neoplasia III, correlation with Ki-67 expression, 76, 51 HPV infection, persistence after therapeutic conization for CIN III, 79, 294 and long-term results, in epithelial ovarian cancer, 78, 21 lymph node metastasis and clear cell histology in ovarian carcinoma limited to pelvis, 79, 251 MAGE-4 protein serum levels, in ovarian cancer, 76, 336 MIB-1 labeling index in stage IB squamous cell cervical carcinoma, 76, 97 NK cell activity in presence of IL-12, for neoadjuvant chemotherapy in cervical carcinoma, 78, 318 p53 and bcl-2 expression in epithelial ovarian carcinoma at median follow-up of 60 months, 77, 278 pretherapeutic tetranectin and CA 125 in recurrent ovarian carcinoma, 79, 416 proliferation assessment with MIB-1 labeling index, in radiation therapy for cervical cancer, 79, 300 residual tumor in barrel-shaped endophytic cervical carcinoma, effects of total radiation dose, 76, 373 serum Cyfra 21-1, SCC-Ag, and TPA levels, in squamous cell cervical carcinoma, 77, 164 stage IVB endometrial carcinoma after cytoreductive surgery, 78, 85 Proliferation assessment with MIB-1 labeling index, as prognostic factor in radiation therapy for cervical cancer, 79, 300 in endometrial carcinoma cells, multiparameter flow cytometric study, 77, 11 Protheses pelvic displacement, exclusion of small intestine from radiation field with after radical hysterectomy, 79, 438 Psychological distress in epithelial ovarian cancer patients, relationship with health and demographic variables, 78, 302 PTEN mutational analysis in cervical carcinoma, 76, 193 repeat tract mutation, absence in endometrial cancers with microsatellite instability, 79, 101 PTH-rp, see Parathyroid hormone-related protein Pyelitis hemorrhagic, with ureteritis and cystitis, secondary to cyclophosphamide, case report and literature review, 76, 223 Q Quality of life after radiotherapy for advanced cervical carcinoma patient’s perspective on physical symptoms, 76, 14 psychological and social effects, 76, 5 in epithelial ovarian cancer patients, relationship with health and demographic variables, 78, 302 value of woman’s perceived, after cervical carcinoma, editorial, 76, 3 R Race clinical outcomes in black versus white women treated with radiotherapy for cervical carcinoma, 79, 357 impact on outcome in invasive cervical carcinoma, 79, 107

Radiosensitivity RU486-induced increase, in dexamethasone treated cervical carcinoma cells through HPV E6/E7 modulation, 77, 177 Radiotherapy adjuvant, and hysterectomy, cost-effectiveness in early stage endometrial carcinoma, 74, 208; letter to editor, 76, 142; reply, 142 in advanced cervical cancer patient’s perspective on physical symptoms, 76, 14 psychological and social effects, 76, 5 in cervical carcinoma clinical outcomes in black versus white women, 79, 357 with concurrent chemotherapy, better treatments that cost more, editorial, 78, 1 with concurrent cisplatin, in cervical cancer, cost effectiveness, 78, 3 in elderly patient, efficacy and toleration, 77, 116 exclusion of small intestine from radiation field with pelvic displacement protheses after radical hysterectomy, 79, 438 extended field, in cervical carcinoma metastatic to para-aortic lymph nodes, survival following, 79, 399 high external parametrial, and high-dose intracavitary brachytherapy, in cervical carcinoma, relationship with radiation proctitis, 79, 406 high-risk, versus chemotherapy or observation after radical hysterectomy, randomized prospective trial, 73, 196; letter to editor, 77, 340; reply, 341 induced fistulas, vaginal reconstruction using bladder/rectal walls, 78, 356 intraoperative, in treatment of pelvic gynecologic malignancies, review of 15 cases, 79, 457 proliferation assessment with MIB-1 labeling index as prognostic factor, 79, 300 radical, for recurrent endometrial cancer, survival and local control, 77, 66 total dose radiation, effects on residual tumor in barrel-shaped endophytic cervical carcinoma dose prognostic significance, 76, 373 K-ras activation and mutation in papillary serous carcinoma of the peritoneum, 77, 105 mutations in uterine papillary serous carcinoma, 77, 439 Rb mutations in uterine papillary serous carcinoma, 77, 439 RCAS1 expression in normal, hyperplastic, and malignant uterine endometrium, clinical significance, 79, 424 Reconstruction vaginal and pelvic floor, at time of pelvic exenteration, morbidity study, 77, 293 Renal transplant lower genital tract neoplasms of female recipients of, human papillomavirus subtypes in, analysis, 79, 220 Retroviruses HPV16 E7 antisense RNA delivery by, effects on CaSki cell tumorigenicity, 78, 293 new generation vector for BCRA1 gene therapy in ovarian cancer, preclinical studies, 79, 471 Reverse transcription polymerase chain reaction cytokeratin-20, in detection of lymphatic micrometastasis in endometrial cancer patients, 77, 399 Rice bran fraction lipoprotein, induction of apoptosis and growth inhibition in cultured human endometrial adenocarcinoma cells, 76, 170 Risk factors endometrial carcinoma, impact of tubal sterilization, 79, 482 for ovarian carcinoma, in central Italy, 79, 50 for recurrent hydatidiform mole, 78, 288

549

CUMULATIVE SUBJECT INDEX RNA telomerase, 2-5A antisense directed against, induction of apoptosis in ovarian carcinoma cell lines, 76, 183 RT-PCR, see Reverse transcription polymerase chain reaction RU486, see Mifepristone

S SCC-Ag, see Squamous cell carcinoma antigen SCID, see Severe combined immunodeficiency Screening cervical, telomerase activity in pap smear-negative exfoliated cervical cells, association with lesions and oncogenic human papillomavirus, 77, 394 endometrial , in asymptomatic postmenopausal patients treated with tamoxifen, value of sonohysterography, 78, 275 ovarian cancer, Stockholm Screening Study, long-term follow-up, 79, 466 transvaginal ultrasound, for early-stage epithelial ovarian carcinoma in asymptomatic women, 77, 350 editorial, 77, 347 SEAP, see Alkaline phosphatase, human secreted Secreted protein, acidic and rich in cysteine and VEGF, immunoreactivity in epithelial ovarian cancer, 78, 336 SEER, see Surveillance Epidemiology and End Results Sentinel node dissection and ultrastaging, in squamous cell vulvar carcinoma, 76, 40; letter to editor, 77, 484; reply, 485 Serosal fluids elevated serum CA 125 levels in hemodialysis patients with, 77, 254 Severe combined immunodeficiency murine– human xenograft model, in development and assessment of general theory of cervical carcinogenesis, 77, 137 Sexual dysfunction after vulvectomy, survey, 77, 73 Signet ring stromal tumor ovarian, occurrence with Brenner tumor, case report, 77, 323 Society of Gynecologic Oncologists Outcomes Task Force endometrial carcinoma, initial experiences, 79, 379 Sonography, see also Sonohysterography; Ultrasonography transvaginal B-mode and color Doppler, combined, in differential diagnosis of ovarian tumors, 77, 78 Sonohysterography for endometrial screening in asymptomatic postmenopausal patients treated with tamoxifen, 78, 275 SPARC, see Secreted protein, acidic and rich in cysteine Splenectomy as surrogate marker for aggressive tumor cytoreduction in ovarian carcinoma, 77, 362 Squamous cell carcinoma arising in mature cystic ovarian teratoma, M-CSF and squamous cell carcinoma antigen as diagnostic markers, 77, 405 Squamous cell carcinoma antigen and leupin/SCCA-2, immunoreactivity in cervical carcinoma, implications for tumor marker detection, 78, 62 and M-CSF, as marker for squamous cell carcinoma arising in mature cystic teratoma of ovary, 77, 405 as prognostic indicator in low-risk stage IB-IIA squamous cell carcinoma of cervix, 76, 103 serum levels, in squamous cell cervical carcinoma, as predictors of lymph node metastasis or prognosis, 77, 164 Staging, see also Ultrastaging cervical carcinoma, utility of cytoscopy in, 76, 200 Stapling surgical, technique for radical hysterectomy, survival, recurrence, and late complications, 79, 281

Stat 3 constitutive activation in human ovarian carcinoma cells, 79, 67 Sterilization tubal, impact on endometrial cancer risk, 79, 482 Stockholm Screening Study ovarian cancer, long-term follow-up, 79, 466 Stress among gynecologic oncologists, Distinguished Professor Series, 76, 301 Struma ovarii malignant, with Graves’ disease, case report, 79, 508 Surgery abdominal sacral colpopexy, in patients with gynecologic cancers, long-term follow-up, case report and literature review, 75, 504; letter to editor, 77, 483; reply, 484 aggressive, with prolonged Pt-based chemotherapy, in long-term ovarian cancer survivor, case report, 78, 261 cytoreductive complete, in epithelial ovarian cancer, effects of tumor site and size, 78, 176 complete salvage, in late recurrent ovarian cancer, 79, 344 value in stage IV epithelial ovarian cancer with hepatic metastases, 78, 171 laparoscopic, subsequent spread of ovarian cancer, report of eight cases, 75, 387; letter to editor, 78, 77; reply, 78 in management of borderline ovarian tumors, survey of Society of Gynecologic Oncologists, 78, 7 second-look, in ovarian carcinoma, opinion in support of, editorial, 79, 337 in squamous cell vulvar carcinoma, clinically based individualization of treatment, 78, 346 Surveillance post-therapy, cervical cancer patients, outcomes analysis, 78, 187 Surveillance Epidemiology and End Results potential insensitive-measure bias in, 77, 450 Survival after extended field irradiation for cervical carcinoma metastatic to paraaortic lymph nodes, 79, 399 after radical hysterectomy using surgical stapling technique, 79, 281 age-specific, in endometrioid adenocarcinoma of uterus, 79, 86 invasive cervical carcinoma, impacts of age, race, and comorbid illness, 79, 107

T Tamoxifen breast cancer patients treated with, endometrial histopathology, review of 700 cases, 78, 181 postmenopausal breast cancer patients treated with endometrial screening, value of sonohysterography, 78, 275 long-term transvaginal ultrasonographic endometrial follow-up, 74, 222; letter to editor, 76, 423; reply, 423 T-cell factor –␤-catenin pathway, activation in ovarian cancer, 77, 97 Telomerase in pap smear-negative exfoliated cervical cells, association with lesions and oncogenic human papillomavirus, 77, 394 Telomerase RNA 2-5A antisense directed against, induction of apoptosis in ovarian carcinoma cell lines, 76, 183 Tenascin as marker for malignant potential in preinvasive breast cancer, 79, 372 Teratoma mature cystic, causing humoral hypercalcemia, PTH-rp in squamous cell carcinoma arising from, immunohistochemical detection, case report, 79, 504

550

CUMULATIVE SUBJECT INDEX

Testis germ cell tumors of, microsatellite instability in, 79, 38 Tetranectin pretherapeutic serum levels, as prognostic factors in recurrent ovarian carcinoma, 79, 416 TGF-␤, see Transforming growth factor-␤ Therapeutic trials patient stratification guidelines, for low-risk gestational trophoblastic tumor, 78, 92 Thrombocytosis significance in locally advanced cervical carcinoma, Gynecologic Oncology Group Study, 78, 137 Thymidine kinase gene herpes simplex , gene therapy, in endometrial carcinoma, 76, 305 Thymidine phosphorylase expression in epithelial ovarian cancer, correlation with angiogenesis, apoptosis, and ultrasound-derived peak systolic velocity, 77, 26 TIMP, see Tissue inhibitor of metalloproteinase Tissue inhibitor of metalloproteinase expression in cyst fluids of ovarian mucinous neoplasms, 78, 106 TIMP-1, protein and mRNA expression in epithelial ovarian tumors, 77, 369 Tissue polypeptide antigen as prognostic indicator in low-risk stage IB-IIA squamous cell carcinoma of cervix, 76, 103 serum levels, in squamous cell cervical carcinoma, as predictors of lymph node metastasis or prognosis, 77, 164 Topoisomerase I elevated, as target for chemoradiation in cervical carcinoma, 79, 272 Topotecan three-day therapy every 21 days in Pt- and paclitaxel-refractory ovarian carcinoma, phase II evaluation, 79, 116 for recurrent epithelial cancers of ovary, fallopian tube, and peritoneum, phase I trial, 79, 495 24-hour continuous infusion, in recurrent, potentially Pt-sensitive ovarian cancer, phase II Gynecologic Oncology Group study, 77, 112 72-hour weekly infusion in Pt- and paclitaxel-resistant ovarian carcinoma, phase II and pharmacokinetic study, 78, 228 effects on CA 125 serum levels in advanced epithelial ovarian carcinoma, 77, 383 in previously-treated cervical squamous cell carcinoma, phase II study, 77, 446 in recurrent fallopian tube carcinoma affecting complete response, case report, 76, 128 Toxicity hematologic, of salvage chemotherapy following stem cell-supported high dose chemotherapy in recurrent ovarian cancer, 77, 48 TPA, see Tissue polypeptide antigen TPS serum levels after three chemotherapy courses in ovarian cancer patients, prognostic significance, 79, 444 Transcriptional factors Ets, expression in ovarian cancer cells lines, correlation to invasive potential, 79, 256 Transforming growth factor-␤ ligand and receptor expression in endocervical cancer, relationship to p27 Kip1 expression, 78, 106 Transplants renal, lower genital tract neoplasms of female recipients of, human papillomavirus subtypes in, analysis, 79, 220 Transsexuals female-to-male, ovarian carcinoma in, case report, 76, 413 Triptorelin effects on EGF-induced c-fos expression in gynecological cancers, 78, 194

Tuberculosis peritonitis in patient presenting with pelvic mass, elevated CA 125, and fever, case report, 77, 471 Tumor burden human secreted alkaline phosphatase as soluble marker for, 78, 373 Tumor suppressor genes PTEN/MMAC1, mutational analysis in cervical carcinoma, 76, 193

U Ultrasonography in assessment of inguinal node status in vulvar cancer, 77, 93 cavitational surgical aspiration by, in treatment of vaginal intraepithelial neoplasia, 78, 242 in classification of asymptomatic adnexal masses, 77, 454 long-term transvaginal endometrial follow-up with, in tamoxifen-treated postmenopausal breast cancer patients, 74, 222; letter to editor, 76, 423; reply, 423 preoperative, prediction of lymph node metastasis in endometrial carcinoma, 71, 424; letter to editor, 79, 522 real-time, in guidance of transvaginal instillation for intraperitoneal chemotherapy of ovarian carcinoma, case report, 79, 332 three-dimensional, and power Doppler, in diagnosis of ovarian lesions, 76, 28 transvaginal assessment of postmenopausal ovaries with, reproducibility, 77, 289 in screening of asymptomatic women for early-stage epithelial ovarian carcinoma, 77, 350 editorial, 77, 347 Ultrastaging and sentinel node dissection, squamous cell vulvar carcinoma, 76, 40; letter to editor, 77, 484; reply, 485 uPAR, see Urokinase-type plasminogen activator receptor Ureteritis with hemorrhagic pyelitis and cystitis, secondary to cyclophosphamide, case report and literature review, 76, 223 Urethral adenocarcinoma female, arising from urethritis glandularis, case report, 79, 511 Urethritis glandularis female urethral adenocarcinoma arising from, case report, 79, 511 Urinary diversion continent, and low-rectal anastomosis, in patients undergoing exenterative procedures for recurrent gynecological cancers, incidence of complications, 78, 208 Urokinase-type plasminogen activator receptor urokinase-type PA, and PAI-2, mRNA expression in normal human endometria and endometrial carcinoma, 79, 244 Urolithiasis after formation of continent urostomy, case report and literature review, 77, 330 Uterine adenocarcinoma papillary serous as manifestation of hereditary breast– ovarian cancer syndrome, 79, 477 p27 and cyclin D1 abnormalities, 77, 439 Uterine adenosarcoma Mu¨llerian, with extrauterine metastatic deposits, management of, case report, 77, 464 Uterine carcinosarcoma ifosfamide with cisplatin in treatment of, phase III trial, 79, 147 Uterine sarcoma single-agent ifosfamide in treatment of, safety and efficacy, 78, 221 Uterine tumors malignant mixed mesodermal, coexistent with choriocarcinoma, case report, 79, 499

551

CUMULATIVE SUBJECT INDEX Uterus fos and jun expression in benign versus malignant tissue, 76, 388 metastasis from heterologous metaplastic breast carcinoma simulating a primary uterine malignancy, case report, 77, 216 V Vaginal adenocarcinoma clear cell, behavior and relationship to intrauterine DES exposure, Distinguished Professor Series, 76, 147 periurethral, of intestinal type, case report and literature review, 77, 478 Vaginal adenosarcoma arising from endometriosis, case report, 76, 123 Vaginal carcinoma cloacogenic, with cardiac metastasis, case report and review of gynecologic malignancies with cardiac metastasis, 76, 208 guidelines for referral to gynecologic oncologist, rational and benefits, 78, S10 squamous cell of neovagina, causing recurrent retroneovaginal fistula in Mayer–Rokitansky–Ku¨ster–Hauser syndrome, case report, 77, 210 primary presenting as cystic pelvic mass, case report, 76, 213 rapid progression in young HIV-infected woman, case report, 78, 380 Vaginal intraepithelial neoplasia cavitational ultrasonic surgical aspiration in treatment of, 78, 235 Vaginal reconstruction at time of pelvic exenteration, morbidity study, 77, 293 using bladder/rectal walls in patients with radiation-induced fistulas, 78, 356 Vascular endothelial growth factor expression in endometrial carcinoma, 77, 413 as prognostic indicator in endodermal carcinomas, 76, 33 and SPARC, immunoreactivity in epithelial ovarian cancer, 78, 336 Vectors new generation retroviral, for BCRA1 gene therapy in ovarian cancer, preclinical studies, 79, 471 VEGF, see Vascular endothelial growth factor Vulva dermatofibrosarcoma protuberans of, case report and literature review, 78, 74 Langerhans’ cell histiocytosis of, case report, 78, 251 Paget’s disease of, pathology, pattern of involvement and prognosis, 77, 183 Vulvar carcinoma complete groin lymphadenectomy with preservation of fascia lata in treatment of, 77, 314 guidelines for referral to gynecologic oncologist, rational and benefits, 78, S11

inguinal node status, ultrasound assessment, 77, 93 Ki-67 expression, correlation with clinical prognostic factors, 76, 51 metachromous, co-occurrence with Fallopian tube metachromous carcinoma, case report, 77, 206 squamous cell allelic imbalance and microsatellite instability phenotype in, 77, 171 clinically based individualization of treatment, 78, 346 sentinel node dissection and ultrastaging in, 76, 40; letter to editor, 77, 484; reply, 485 stage IA, long-term results, 76, 24 Vulvar intraepithelial neoplasia allelic imbalance and microsatellite instability phenotype in, 77, 171 stage III, Ki-67 expression, correlation with clinical prognostic factors, 76, 51 Vulvar reconstruction with anterolateral thigh vastus lateralis myocutaneous flap after radical vulvectomy, case report, 78, 391 Vulvar tumors granular cell, clinical characteristics, histology, and surgical treatment, 77, 310 Vulvectomy radical, vulvar reconstruction with anterolateral thigh vastus lateralis myocutaneous flap following, case report, 78, 391 sexual dysfunction following, survey, 77, 73

W Wilms’ tumor cervical, case report and literature review, 76, 107 WT1 gene alterations in papillary serous carcinoma of peritoneum, 76, 369

X Xenografts ovarian carcinoma intraperitoneal photoimmunotherapy in nude mice using charged photoimmunoconjugates, 76, 397 panel for drug screening and determination of role of glutathione detoxification system, 76, 362